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ABSTRACT 
Alzheimer’s disease (AD) continues to disrupt the lives of millions of patients and 
caregivers around the world. The few drugs currently used for AD have modest effects 
on the symptoms and do not prevent the progression of the disease into total memory 
loss and death. With the increase in the number of AD cases and the high social and 
economical costs of the disease, there is a great need to find disease-modifying 
therapeutics that target the core pathology of the disease as well as improve the 
symptoms and the patients’ everyday quality of life. Two types of pathological 
aggregates are found in AD. The senile plaques are composed of amyloid beta (Aβ), 
which is cleaved off the amyloid precursor protein (APP) by beta-site APP cleaving 
enzyme (BACE) and γ-secretase. The other deposits are the neurofibrillary tangles 
(NFTs), which are mainly composed of hyperphosphorylated tau. These aggregates 
and factors involved in the production or clearance of Aβ, as well as the 
phosphorylation of tau are being investigated for potential AD treatments but so far no 
successful drug candidate has been found. The transcription factor specificity protein 1 
(Sp1) has been linked to pathological intermediates in AD. Sp1 regulates the 
transcription of APP, BACE1, tau and its cyclin dependent kinase-5 (CDK5) 
activators p39 and p35. Previous experiments from our lab have shown that AD like 
pathology develops later in vitro and in vivo following early lead (Pb) exposure 
including elevated levels of SP1, APP, Aβ, tau and CDK5 as well as cognitive decline 
in mice. Studies from our lab demonstrated that decreasing Sp1 protein (SP1) levels 
following oral administration of tolfenamic acid to mice was able to reduce APP and 
Aβ levels and improve cognition. In this dissertation, we first provided an introduction 
to AD with a review on the role of epigenetics in the disease and the various means by 
which transcriptional pathways can provide therapeutic alternatives for AD. We then 
examined the ability of tolfenamic acid to affect the expression of AD targets that are 
regulated by Sp1 including tau, phosphorylated tau, CDK5 and BACE1 in mice by 
using Western blot, real time PCR and enzyme activity assays. In addition, we studied 
the ability of tolfenamic acid to prevent the increase in SP1, APP and Aβ in 
differentiated neuroblastoma cells that was triggered by prior exposure to Pb. After 
treatment of cells with Pb, tolfenamic acid or both, we used real time PCR, ELISA and 
Western blot analyses to examine the effects of both agents on AD related 
intermediates compared to control. In addition to providing a summary of the current 
knowledge on epigenetic therapeutic targets for AD, the major findings of this 
dissertation provide proof that tolfenamic acid was able to decrease the transcription 
and translation of proteins involved in AD like tau, BACE1 and CDK5 as well as the 
phosphorylation of tau in mice. Moreover, in differentiated neuroblastoma cells, 
tolfenamic acid decreased the expression of SP1, APP gene and Aβ which was 
previously upregulated by Pb. Hence, tolfenamic acid represents a novel oral drug 
candidate that can be beneficial for AD by affecting both the amyloid and tangle 
pathology of the disease through a unique transcription driven mechanism.  
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PREFACE 
This dissertation was prepared following the manuscript format. It was divided into 
four manuscripts that relate to the effects of tolfenamic acid on Alzheimer’s disease 
(AD) associated genes and proteins. The first manuscript is a review article on 
epigenetic treatments for AD as an emerging field of study, it was prepared following 
the guidelines of Pharmacology and Therapeutics journal. The second manuscript 
examines the effects of tolfenamic acid administration on the tau pathway of AD in 
mice, it was prepared according to the Journal of Neuroscience guidelines. The third 
manuscript examines the consequences of tolfenamic acid exposure in APP transgenic 
mice on the enzyme β-secretase, it was written in accordance with the 
Neuropharmacology journal. The last manuscript summarizes our observations after 
the sequential exposure of neuroblastoma cells to Pb and tolfenamic acid and was 
prepared following Toxicology and Applied Pharmacology guidelines. 
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Abstract 
 
Alzheimer’s disease (AD) is the most common type of dementia in the elderly. It is 
characterized by the deposition of two forms of aggregates within the brain, the 
amyloid plaques and tau neurofibrillary tangles. Currently, no disease-modifying 
agent is approved for the treatment of AD. Approved pharmacotherapies target the 
peripheral symptoms but they do not prevent or slow down the progression of the 
disease. Although several disease-modifying immunotherapeutic agents are in clinical 
development, many have failed due to lack of efficacy or serious adverse events. 
Epigenetic changes including DNA methylation and histone modifications are 
involved in learning and memory and have been recently highlighted for holding 
promise as potential targets for AD therapeutics. Dynamic and latent epigenetic 
alterations are incorporated in AD pathological pathways and present valuable 
reversible targets for AD and other neurological disorders. The approval of epigenetic 
drugs for cancer treatment has opened the door for the development of epigenetic 
drugs for other disorders including neurodegenerative diseases. In particular, methyl 
donors and histone deacetylase inhibitors are being investigated for possible 
therapeutic effects to rescue memory and cognitive decline found in such disorders. 
This review explores the area of epigenetics for potential AD interventions and 
presents the most recent findings in this field. 
 
Keywords:  
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DNA methylation 
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Histone modification 
Memory 
Therapy 
 
Abbreviations: Aβ, amyloid β; AD, Alzheimer’s disease; APP, amyloid β precursor 
protein; BACE, β-site APP cleaving enzyme; CBP, CREB binding protein; CREB, 
cAMP response element-binding protein; CSF, cerebrospinal fluid; DNMT, DNA 
methyltransferase; FAD, familial AD; HAT, histone acetyltransferase; HDAC, histone 
deacetylase; LOAD, late onset AD; MeCP2, methyl CpG binding protein 2; NFTs, 
neurofibrillary tangles; PS, presenilin; SAM, S-adenosyl methionine; SIRT, sirtuin; 
Sp1, specificity protein 1. 
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1. Introduction 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, with over 35 
million cases worldwide (Selkoe, 2012). The four acetylcholinesterase inhibitors, 
donepezil rivastigmine, galantamine and tacrine, along with the NMDA receptor 
antagonist memantine are the only FDA-approved drugs for AD; however, they 
merely target the symptoms and do not prevent the progressive loss of memory, 
cognitive and executive functions in AD patients. With the increase in life expectancy 
and the absence of disease-modifying agents, the number of people with AD is 
expected to triple within the upcoming 40 years (Barnes & Yaffe, 2011; Huang & 
Mucke, 2012; Tricco et al., 2012). The annual costs for AD and other dementias in the 
US in 2013 are estimated to be over $200 billion and are expected to reach $1.2 
trillion in 2050 (Alzheimer's Association, 2013). With such a heavy socioeconomic 
burden, there is an urgent need to find novel and improved treatments for AD. 
Throughout the last century, the advances acquired in health related fields were able to 
increase the lifespan of AD patients, yet this needs to be matched with discoveries that 
improve the quality of life of people with this debilitating disorder. New targets should 
be identified and investigated for possible AD therapeutics that tackle its core 
pathophysiology as well as prevent the decline in memory and cognitive functions 
associated with the disease. 
AD is characterized by progressive loss of memory and other cognitive and executive 
functions, with two types of pathological deposits found in the brain, the extracellular 
amyloid β (Aβ) plaques and the intracellular tau neurofibrillary tangles (NFTs). Senile 
plaques are mainly composed of Aβ which is cleaved off the larger amyloid β 
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precursor protein (APP) by β-site APP cleaving enzyme (BACE), also known as β-
secretase, and γ-secretase (Citron et al., 1995; Shoji et al., 1992). According to the 
amyloid hypothesis, Aβ and its aggregates are responsible for the neurodegeneration 
and dementia in AD through mechanisms that involve disturbances in calcium 
homeostasis which make cells more vulnerable to toxicants that can cause further 
damage and NFTs (Hardy & Higgins, 1992; Mattson et al., 1992; Selkoe, 1993). The 
hypothesis was supported by the fact that mutations on APP are connected to 
hereditary types of AD (Hardy & Higgins, 1992). Early onset familial AD (FAD) 
could also be due to mutations on genes encoding the presenilin (PS) membrane 
proteins PS1 and PS2 (Czech et al., 2000; Tanzi et al., 1996). PS mutations increase 
the production of the more aggregative 42 amino acid-long Aβ (Aβ42) from APP and 
elevated Aβ42 levels were observed in the blood and brains of FAD patients with PS 
abnormalities (Czech et al., 2000). In addition, neurons lacking the PS1 gene fail to 
produce Aβ peptides (De Strooper et al., 1998; Naruse et al., 1998). PS1 was found to 
be related to the enzyme γ-secretase (De Strooper et al., 1998; Shimojo et al., 2007). 
These findings suggest that Aβ and its aggregates are involved in the pathology of AD 
as proposed in the amyloid hypothesis. 
NFTs are composed of tau protein which belongs to a family of microtubule-
associated proteins that normally promote microtubule assembly (Weingarten et al., 
1975). When hyperphosphorylated, tau loses its normal function and becomes prone to 
form pathological aggregates causing disorders known as tauopathies of which AD is 
the most common (Alonso et al., 1997; Lee et al., 2001). Both Aβ and tau have been 
associated with neurodegeneration and memory decline and have been extensively 
 7 
 
targeted for AD interventions such as immunotherapeutics, enzyme modulators, and 
aggregation inhibitors (Hardy & Higgins, 1992; Hardy & Selkoe, 2002; Hutton et al., 
1998; Iqbal et al., 2009; Lee et al., 2001; Selkoe, 1993). 
Epigenetics deals with acquired and heritable modifications on DNA that regulate the 
expression and functions of genes without affecting the DNA nucleotide sequence. 
These include DNA methylation and hydroxymethylation, histone modifications and 
non-coding RNA regulation. Histone modifications consist of acetylation, 
methylation, crotonylation, ubiquitination, sumoylation, phosphorylation, 
hydroxylation and proline isomerization (Davie & Spencer, 1999; Houston et al., 
2013; Kouzarides, 2007; Peterson & Laniel, 2004). All these pathways act as 
mediators between the environment and the genome, these epigenetic changes are 
activated by various conditions such as stress or exposure to environmental toxicants 
and in turn they result in a variety of responses including gene transcription or 
silencing. Epigenetic changes are dynamic and unlike genetic mutations, they can be 
reversed for therapeutic purposes by targeting enzymes or other factors that control or 
maintain them (Caraci et al., 2012; Feinberg, 2008; Henikoff & Matzke, 1997; Liu et 
al., 2008; Mill, 2011). As changes within the genetic makeup itself are limited and the 
environment cannot freely amend the DNA sequence, epigenetics is the mechanism 
through which the environment can affect gene expression and function which can be 
employed as a medical intervention for diseases where epigenetics play a pathological 
role (Jaenisch & Bird, 2003; Mill, 2011). Furthermore, some age related changes are 
also mediated through epigenetics (Feinberg, 2008).  
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The majority of AD cases are sporadic or late onset AD (LOAD). Only about 5% of 
cases are familial or early onset AD which is associated with rare mutations on the 
APP, PS1 and PS2 genes (Goate et al., 1991; Sherrington et al., 1995; Tanzi, 2012). 
The sporadic nature of AD suggests that epigenetics plays an important role in the 
pathology of the disease; a hypothesis that is supported by recent findings from our 
laboratory and others (Lahiri et al., 2009; Lahiri et al., 2008; Mastroeni et al., 2011; 
Mill, 2011; Wang et al., 2008a; Wu et al., 2008b; Zawia & Basha, 2005; Zawia et al., 
2009). This review explores epigenetic mechanisms as possible targets for AD 
therapeutics and highlights the current status of epigenetics in AD pathology and drug 
discovery. 
1.1. Epigenetics of the brain and memory formation 
Epigenetic dynamics within cells play a major role in their differentiation and in 
determining their functional type as hepatocytes in the liver, neurons in the brain, skin 
cells, or other cells, as well as becoming cancerous or not (Chadwick, 2012; Feinberg, 
2008). Epigenetics is involved in various brain related disorders and physiologic 
responses that genetics alone does not completely explain including AD, depression, 
schizophrenia, glioma, addiction, Rett syndrome, alcohol dependence, autism, 
epilepsy, multiple sclerosis and stress (Heim & Binder, 2012; Inkster et al., 2013; 
Jaenisch & Bird, 2003; Kreth et al., 2012; Maric & Svrakic, 2012; Maze & Nestler, 
2011; Mifsud et al., 2011; Nguyen et al., 2010; Orr et al., 2012; Qureshi & Mehler, 
2010; Shahbazian & Zoghbi, 2002; Taqi et al., 2011; Zawia et al., 2009). As neurons 
do not divide and cannot be replaced after degeneration, epigenetic changes resulting 
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in neuronal dysfunction need to be targeted and modified to prevent 
neurodegeneration (Bird, 2007; Selvi et al., 2010). 
Recent studies have pointed out the importance of epigenetics in brain development 
and functions including learning and memory (Feng et al., 2007; Miller & Sweatt, 
2007; Molfese, 2011; Sultan & Day, 2011). In particular, DNA methylation and 
histone acetylation both play an important role in memory formation (Levenson et al., 
2006; Miller et al., 2008). Other histone modifications involved in memory are 
methylation and phosphorylation (Chwang et al., 2006; Gupta et al., 2010; Molfese, 
2011). 
DNA methylation is catalyzed by DNA methyltransferases (DNMTs) in the presence 
of the methyl donor S-adenosyl methionine (SAM) (Yen et al., 1992). The DNMT 
family of enzymes includes DNMT1, DNMT2, DNMT3a, and DNMT3b (Okano et 
al., 1999). It is found that DNMT3a and DNMT3b are responsible for de novo 
methylation and establish DNA methylation patterns while DNMT1 has preference for 
hemi-methylated DNA (Chen et al., 2003; Hsieh, 1999; Okano et al., 1999). DNA 
methylation occurs on the 5’ position of cytosine in CpG rich regions (Bird, 1986). 
This epigenetic mechanism regulates gene transcription and plays a particular role in 
memory functions (Day & Sweatt, 2010; Korzus, 2010; Liu et al., 2009). Memory and 
learning abilities decline with age which correlates with an overall reduction in DNA 
methylation (Liu et al., 2009). Furthermore, methylation on certain locations of the 
APP promoter in the human cortex is reduced with age (Tohgi et al., 1999). 
DNMTs are considered crucial for memory functions (Miller & Sweatt, 2007). 
DNMTs regulate methylation within the promoter of reelin, an extracellular 
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glycoprotein that is involved in memory formation in the adult brain (Levenson et al., 
2006; Weeber et al., 2002). Protein levels of DNMT1 and DNMT3a are reduced in the 
cortex of aged monkeys compared to early time points (Bihaqi et al., 2011). Moreover, 
conditional knockout mice lacking the expression of Dnmt1 and Dnmt3a genes in 
forebrain neurons perform worse on the Morris water maze hippocampus related 
memory task than wild-type littermates or knockout mice lacking the expression of 
only one of the genes (Feng et al., 2010). The gene expression of Dnmt3a2 decreases 
with age in mouse cortex and hippocampus (Oliveira et al., 2012). This age-related 
decline in Dnmt3a2 gene expression is linked to memory decline that can be recovered 
by restoring DNMT3a2 levels (Oliveira et al., 2012). 
Hydroxylation of 5-methylcytosine to 5-hydroxymethylcytosine by ten-eleven 
translocation (TET) enzymes is an important regulatory pathway involved in brain 
development, aging and disease (Szulwach et al., 2011). Levels of 5-
hydroxymethylcytosine are significantly higher in neurons than in cells of other tissues 
(Globisch et al., 2010; Szulwach et al., 2011). DNA hydroxymethylation, levels of 5-
hydroxymethylcytosine and 5-methylcytidine increase with age, and alterations in 
DNMT3a have also been reported with aging in mouse hippocampus (Chouliaras et 
al., 2011; Chouliaras et al., 2012a; Chouliaras et al., 2012b). Such epigenetic changes 
could be prevented by 50% caloric restriction diet throughout the mice lifetime after 
weaning (Chouliaras et al., 2011; Chouliaras et al., 2012a; Chouliaras et al., 2012b).  
Moreover, mutations on methyl CpG binding protein 2 (MeCP2) may contribute to the 
development of Rett syndrome; a life-long neurodevelopmental disorder with marked 
learning disabilities (Amir et al., 1999). Other neurological abnormalities such as 
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autism and infantile encephalopathy have been associated with disturbances in MeCP2 
(Chahrour et al., 2008; Moretti & Zoghbi, 2006). MeCP2 binds to methylated cytosine 
in CpG dinucleotides and inhibits or promotes gene expression by recruiting 
transcription repressors or activators like cAMP response element-binding protein 1 
(CREB1) (Chahrour et al., 2008; Jones et al., 1998; Nan et al., 1998). This also 
involves MeCP2 binding to histone deacetylase complex (Jones et al., 1998; Nan et 
al., 1998). MeCP2 levels are found to decrease with age in primates (Bihaqi et al., 
2011). 
Histone acetylation is also involved in the regulation of learning and memory 
(Levenson et al., 2004; Martin & Sun, 2004). The most widely studied histone 
modification is regulated by two groups of enzymes, histone acetyltransferases 
(HATs) and histone deacetylases (HDACs). The HDACs family of enzymes has been 
studied extensively for implications in cancer. Aberrant overexpression of various 
HDACs has been reported in different cancer types including gastric, pancreatic, 
breast, lung and colon cancer (Barneda-Zahonero & Parra, 2012; Johnstone, 2002; 
New et al., 2012). Many HDAC inhibitors are in clinical trials for cancer therapy, 
vorinostat and romidepsin have been approved by the FDA for cutaneous T-cell 
lymphoma (Kim et al., 2012; Mann et al., 2007; Nebbioso et al., 2012). There are 18 
HDACs identified that belong to four classes I, II, III and IV according to their 
sequence homology (Xu et al., 2007). Class I HDAC2, class IIb HDAC6 and class III 
sirtuins (SIRTs) 1 and 2 are linked to AD pathology (de Oliveira et al., 2012; 
Karagiannis & Ververis, 2012). Acetylation of histone H3 in the hippocampus 
accompanies long-term memory formation in rats as determined in hippocampal 
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tissues collected 1 hour after fear conditioning experiments (Levenson et al., 2004). 
Increasing histone acetylation by the administration of the HDAC inhibitor sodium 
butyrate to rats prior to contextual fear conditioning improves memory formation 
(Levenson et al., 2004). Class I HDAC inhibitors sodium butyrate, sodium valproate 
and vorinostat enhance cognition in APP/PS1 double transgenic AD mouse model as 
evaluated by contextual fear conditioning tests (Kilgore et al., 2010). Overexpression 
of HDAC2 and not HDAC1, both Class I HDACs, in mice impairs memory and 
chronic administration of the HDAC inhibitors vorinostat or sodium butyrate enhances 
cognition (Guan et al., 2009). HDAC2 knockout mice display improved memory in 
fear conditioning experiments over wild-type mice (Guan et al., 2009). Consequently, 
downregulation or inhibition of HDACs 2 and 6 constitute important therapeutic 
targets for memory related disorders. 
1.2. Epigenetic changes in AD 
1.2.1. Histone modifications in AD 
Increased levels of HDAC2 have been associated with cognitive impairment in CK-
p25 AD mouse model which seems to be mediated through glucocorticoid receptor 
induced HDAC2 transcription (Graff et al., 2012). Postmortem studies reported that 
HDAC2 and not HDAC1 or HDAC3 is increased within the hippocampus of AD 
patients (Graff et al., 2012). Class II HDAC6 levels are elevated in AD cortex and 
hippocampus by 52% and 91% respectively (Ding et al., 2008). Tau co-localizes with 
HDAC6 in AD hippocampus and in vitro, and downregulation of HDAC6 decreases 
tau phosphorylation at Thr231 (Ding et al., 2008). Hyperphosphorylation of tau 
inhibits its normal functions and promotes its aggregation (Alonso et al., 1997). In 
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particular tau phosphorylation at Thr231 restrains its normal function of binding to 
microtubules (Sengupta et al., 1998). Class III HDACs or sirtuins is a family of 
enzymes that includes seven members named SIRT1-7 (Gray & Ekstrom, 2001). In 
addition to histones, SIRTs are responsible for deacetylation of other molecules like 
some proteins involved in AD pathology. For example SIRT1 accounts for tau 
deacetylation which is considered neuroprotective while tau acetylation contributes to 
tau dysfunction and aggregation (Cohen et al., 2011; Min et al., 2010; Stunkel & 
Campbell, 2011). SIRT1 is lower in the AD cortex which correlates with presence of 
tau pathology and memory impairment (Julien et al., 2009). There is evidence that 
SIRT1 also stimulates α-secretase which cleaves APP within the Aβ sequence and 
protects against Aβ accumulation (Donmez et al., 2010; Raghavan & Shah, 2012; 
Wang et al., 2010). SIRT1 is the most studied sirtuin, other sirtuins are also expressed 
in the brain and SIRT2 has been presented as a drug target for neurodegenerative 
diseases such as Parkinson’s and Huntington’s diseases (de Oliveira et al., 2012). 
1.2.2. DNA methylation in AD 
DNA methylation and factors such as DNMT1 are significantly reduced in neurons of 
entorhinal cortex layer II in AD patients (Mastroeni et al., 2010). Reductions in 
methylation are particularly localized in tangles containing neurons (Mastroeni et al., 
2010). Other studies have demonstrated that there is abnormal methylation in AD 
patients (Bakulski et al., 2012; Wang et al., 2008a). When studying DNA methylation 
within the cerebral cortex of AD and control subjects, two out of the fifty loci 
examined were differentially methylated in AD which represent an acceleration of 
aging-linked alterations (Siegmund et al., 2007). In an AD discordant pair of 
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monozygotic twins, extensive plaques and NFTs were present and less methylation 
was found in the cortex of the AD twin compared to the non-AD twin (Mastroeni et 
al., 2009). However, some studies found no differences in the methylation patterns of 
AD-related genes (Barrachina & Ferrer, 2009). The difficulties in obtaining 
postmortem AD brain tissues for such studies and the variability among the available 
tissues as well as the different end points of methylation analyzed within these studies 
account for their various findings.  
The promoter region within the APP gene is GC rich suggesting that it can be 
modulated through methylation (Pollwein et al., 1992). APP promoter displays 
differential methylation within the human brain (Rogaev et al., 1994). 
Hypomethylation of the APP promoter was reported to correlate with APP 
overexpression in AD (West et al., 1995). DNA methylation controls BACE and PS1 
expression and consequently Aβ levels (Fuso et al., 2005). PS1 expression and 
methylation is altered in LOAD (Wang et al., 2008a). However, the changes on PS1 
gene methylation in AD brains were not significant (Wang et al., 2008a). Another 
study did not detect significant changes in PS1, APP and tau genes methylation in the 
cortex and hippocampus of AD patients compared to controls (Barrachina & Ferrer, 
2009). Lower paternal age was significantly associated with the increase in LOAD risk 
which might involve DNA methylation (Farrer et al., 1991). The challenges in 
acquiring and handling human brain tissues make it difficult to have a large number of 
matched controls and AD samples, however the available studies along with the 
sporadic and non-mendelian inheritance nature of the disease suggest that epigenetics 
is indeed involved in AD. Further research is needed to examine the epigenetic 
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changes affecting AD biomarkers including APP, tau, BACE, PS1 and PS2 among 
others, as well as global gene methylation patterns which would help with the early 
diagnosis of the disease.  
1.2.3. Non-coding RNA in AD 
Non-coding RNA can influence gene expression via epigenetic mechanisms affecting 
DNA methylation, histone modifications and chromatin remodeling (Costa, 2008). 
Various microRNAs are differentially expressed in AD and alter the expression of AD 
pathological intermediates (Cogswell et al., 2008; Nunez-Iglesias et al., 2010; Provost, 
2010). An example is microRNA-101 which negatively regulates APP levels and is 
reduced within the brain cortex of AD patients (Hebert et al., 2008; Vilardo et al., 
2010). Another example is microRNA-107 which is lowered early in AD and regulates 
BACE1 expression (Wang et al., 2008b). BACE1-AS is a long non-coding RNA 
antisense transcript of BACE1 that improves BACE1 stability and expression and is 
upregulated in the hippocampus and cortex of AD patients (Faghihi et al., 2008). 
Additional changes on non-coding RNAs are reported in AD and have been reviewed 
recently (Schonrock & Gotz, 2012). However, due to the current limitations and the 
absence of methods that can target or modify non-coding RNAs for therapeutic 
purposes, only few are mentioned within this review. 
2. Epigenetic therapeutic approaches for AD  
2.1. HDAC inhibitors 
HDAC inhibitors show promise for cognitive improvement and are being considered 
for drug development for AD (Abel & Zukin, 2008; Fischer et al., 2007; Guan et al., 
2009). Epigenetic changes play a role in cognitive decline and reversing such changes 
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by inhibiting HDAC2 improves memory and cognitive functions (Graff et al., 2012). 
Treatment of hippocampal neurons with Aβ promotes HDAC2 transcription 
suggesting that the traditional target of Aβ lowering in AD should be complemented 
with the reversal of epigenetic changes that were caused by increased Aβ levels (Graff 
et al., 2012). This might explain why Aβ lowering is not always successful in 
improving memory and cognitive deficits when subsequent epigenetic changes are not 
reversed as well (Graff et al., 2012). Crebinostat, an HDAC inhibitor, improves 
memory in mice (Fass et al., 2013). Administration of any of the three Class I HDAC 
inhibitors sodium valproate, sodium butyrate and vorinostat, which is an HDAC 
inhibitor approved by the FDA for cancer, improve memory in the APPswe/PS1dE9 
AD mouse model (Kilgore et al., 2010). Hence, HDAC inhibitors could be promising 
therapeutic agents for AD and other disorders associated with dementia and cognitive 
impairments. 
Valproic acid, which is used as an anticonvulsant in epileptic patients and as a mood 
stabilizer in bipolar disorder patients (Phiel et al., 2001), is a known HDAC inhibitor 
and has therefore been proposed for use in cancer and AD (Gottlicher et al., 2001; 
Kramer et al., 2003; Nalivaeva et al., 2009). In addition, valproate seems to have 
multi-target effects that can be useful for AD including inhibition of the enzyme 
responsible for tau phosphorylation glycogen synthase kinase 3 beta (GSK3β) (Loy & 
Tariot, 2002). Valproic acid lowers Aβ in the PDAPP transgenic mouse model of AD 
(Su et al., 2004). However, in a 2-year clinical trial, valproate did not improve 
cognitive function or slow memory decline in moderate AD patients and was 
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associated with adverse effects such as somnolence, tremor, weakness and dyspnea 
(Fleisher et al., 2011; Tariot et al., 2011).  
Another HDAC inhibitor, sodium phenylbutyrate was found to improve memory and 
lower tau phosphorylation by GSK3β in APPswe transgenic AD mice (Ricobaraza et 
al., 2009). EVP-0334 is an HDAC inhibitor developed for AD by EnVivo 
Pharmaceuticals that successfully completed phase I clinical trials and was deemed 
safe for further testing, however, detailed information on the trial have not been made 
available yet (Arrowsmith et al., 2012; Caraci et al., 2012; Mack, 2010). A class II 
HDAC inhibitor referred to as W2 lowers Aβ, tau phosphorylated at Thr181 and 
improves cognition in hAPP transgenic mice (Sung et al., 2013). The authors also 
found that W2 and I2, a class I and II HDAC inhibitor, both downregulate genes 
involved in Aβ production and promote genes responsible for Aβ degradation in vitro 
(Sung et al., 2013). 
2.2. Sirtuins 
Class III HDACs or SIRTs are epigenetic targets for cancer and AD (Albani et al., 
2010; Huber & Superti-Furga, 2011; Outeiro et al., 2008). The natural product found 
in red grapes skin and wine resveratrol is a SIRT1 activator that improves cognition in 
mice (Kim et al., 2007). However, resveratrol cognitive benefits involve other 
mechanisms besides SIRT1 activation and its epigenetic functions (Huber & Superti-
Furga, 2011; Kim et al., 2007). A phase II study is currently recruiting mild to 
moderate AD patients to study the effects of resveratrol on AD biomarkers including 
cerebrospinal fluid (CSF) tau and Aβ levels as well as memory and daily performance 
using tests like Mini-Mental State Examination (MMSE) and Alzheimer's Disease 
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Assessment Scale-Cognitive (ADAS-Cog) (ClinicalTrials.gov., identifier: 
NCT01504854). Two SIRT activators developed by GSK were in phase I clinical 
trials, SRT2104 and SRT2379, recently the results from one of the trials were 
published and showed that SRT2104 was well tolerated by human subjects and 
suitable for further clinical trials (Hoffmann et al., 2013; Townsend, 2011). 
Interestingly, the nonselective SIRT inhibitor nicotinamide lowers phosphorylated tau 
and improves cognition in mice demonstrating that SIRT modulation involves 
complex mechanisms (Green et al., 2008; Stunkel & Campbell, 2011). Nicotinamide is 
in phase II clinical trial for AD (ClinicalTrials.gov., identifier: NCT00580931). 
Furthermore, administration of the SIRT2 inhibitor AK1 directly into the hippocampus 
protects against neurodegeneration in tau transgenic mice without altering tau tangles 
(Spires-Jones et al., 2012). 
2.3. HATs 
Less attention has been given to HAT enzymes as epigenetic targets for AD. Three 
HATs are involved in memory formation CREB binding protein (CBP), p300 and 
p300/CBP associated factor (PCAF) which might represent more specific targets than 
HDACs (Korzus et al., 2004; Selvi et al., 2010). CBP plays an important role in 
memory as CBP deficient mice display impaired long-term memory formation (Oike 
et al., 1999; Wood et al., 2005). In humans, mutations on the CBP gene result in 
Rubinstein-Taybi syndrome which is characterized by mental retardation (Petrij et al., 
1995; Rubinstein & Taybi, 1963). Inducing the expression of CBP within the brains of 
3xTg-AD triple transgenic AD mouse model recovers the impaired memory functions 
in these mice (Caccamo et al., 2010). On the other hand, inhibition of the HAT p300 
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by using the commercially available p300 inhibitor C646 reduces the levels of 
acetylated tau and phosphorylated tau at Ser202 in vitro (Min et al., 2010). The natural 
plant product curcumin possesses p300/CBP HAT inhibitor activity and is in phase II 
clinical trial to study its cognitive effects and Aβ lowering potential in AD patients 
(Balasubramanyam et al., 2004; ClinicalTrials.gov., identifier: NCT01383161; Marcu 
et al., 2006). Previous trials with a smaller number of AD subjects reported no 
significant changes between curcumin- and placebo- treated groups (Hamaguchi et al., 
2010; Ringman et al., 2012). While in transgenic animal models, curcumin decreased 
oxidative damage and Aβ pathology by affecting anti-inflammatory pathways (Begum 
et al., 2008; Hamaguchi et al., 2010; Lim et al., 2001; Yang et al., 2005). 
2.4. DNA methylation 
There are multiple ways for targeting DNA methylation for therapeutic purposes 
(Klose & Bird, 2006). DNA methylation affects the expression of the AD-related 
intermediates APP, PS1 and Aβ (Fuso et al., 2005). It has been hypothesized that 
hypomethylation of the promoter regions of such genes like PS1 leads to the 
overexpression of their products including Aβ (Mulder et al., 2005). Overexpression 
of DNMT3a2 within the hippocampus of old mice increases overall methylation and 
improves memory (Oliveira et al., 2012). 
The levels of the methyl donor SAM are lower in the CSF and within the brains of AD 
patients (Bottiglieri et al., 1990; Bottiglieri et al., 1994; Morrison et al., 1996). 
However, in another study, there was no difference in SAM-CSF levels in AD patients 
vs. healthy subjects (Mulder et al., 2005). Nevertheless, treatment with SAM reduces 
BACE1, PS1 and Aβ production in vitro in human neuroblastoma cells (Fuso et al., 
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2005; Scarpa et al., 2003). Moreover, administration of SAM adjunct to 
antidepressants in depressed patients enhances their cognitive symptoms and ability to 
remember as determined by cognitive and physical symptoms questionnaire (CPFQ) 
(Levkovitz et al., 2012). 
Betaine, the methyl donor used conventionally for homocystinuria treatment (Key, 
2000), was tested in 8 AD patients for 24 weeks and failed to demonstrate cognitive 
improvement (Craig, 2004; Knopman & Patterson, 2001). However, the small number 
of patients and the lack of a placebo-treated control group suggest that further trials 
are needed to properly evaluate betaine’s efficacy in AD (Knopman & Patterson, 
2001), especially that elevated homocysteine has been associated with dementia and 
AD and betaine lowers homocysteine (Seshadri et al., 2002). In a more recent study in 
mice, betaine was able to improve memory that was compromised by prior 
lipopolysaccharide administration (Miwa et al., 2011). 
2.5. Non-coding RNA 
Several non-coding RNAs are involved in AD pathology and could present specific 
diagnostic and therapeutic targets for the disease (Costa, 2008; Provost, 2010). These 
include BACE1-AS, microRNA-34c, microRNA-101, and microRNA-107 (Cogswell 
et al., 2008; Faghihi et al., 2008; Vilardo et al., 2010; Wang et al., 2008b; Zovoilis et 
al., 2011). However, concerns about ways to alter such targets, off target effects, and 
delivery methods still need to be adequately addressed before having epigenetic 
treatments capable of affecting non-coding RNAs. Targeting non-coding RNA regions 
on APP by the antibiotic erythromycin, the antidepressant paroxetine and N-acetyl 
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cysteine has been found to reduce Aβ in TgCRND8 transgenic mice (Tucker et al., 
2005; Tucker et al., 2006). 
2.6. Beyond epigenetics: Epigenetics and transcription 
Epigenetics is an important mediator that influences DNA transcription and 
translation. The aim of AD therapy is to enhance the transcription of genes involved in 
memory formation and reduce the transcription of pathogenic intermediates in the 
disease process like tau, APP, and BACE1. Hence, transcription factors constitute 
valid targets for developing novel treatments for AD. One of the important 
transcription factors for learning and memory is CREB (Silva et al., 1998). CREB is 
an essential mediator of memory improvement following HDAC inhibition as CREB 
has histone acetylation activity through recruitment of the histone acetyltransferase 
CBP (Vecsey et al., 2007). HDAC inhibitors, such as phenylbutyrate or crebinostat 
promote the transcription of genes involved in memory functions as seen with 
crebinostat which upregulates the CREB target gene early growth response 1 (egr1), 
which is involved in memory formation (Fass et al., 2013; Ricobaraza et al., 2009). A 
clinical trial studying the effects of the antiplatelet drug cilostazol on cognition in AD 
patients co-administered with donepezil is currently in progress (ClinicalTrials.gov., 
identifier: NCT01409564). The rationale behind choosing cilostazol is to promote the 
phosphorylation of CREB which regulates its activity and consequential expression of 
genes that are controlled by CREB (Bito et al., 1996; ClinicalTrials.gov., identifier: 
NCT01409564; Silva et al., 1998). Cilostazol protects against Aβ triggered cognitive 
impairment in mice and improves memory following cerebral hypoperfusion damage 
in rats (Hiramatsu et al., 2010; Watanabe et al., 2006). 
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An important transcription factor involved in AD is specificity protein 1 (Sp1). It 
binds to GC-rich regions within the promoters of APP, tau and BACE1 and 
upregulates their expression (Docagne et al., 2004; Hoffman & Chernak, 1995; 
Pollwein et al., 1992). Sp1 is able to bind to CpG sites in genes promoters that have 
such specific binding motifs and activate their transcription whether they are 
methylated or non-methylated (Holler et al., 1988). Furthermore, Sp1 can trigger 
epigenetic modifications as it regulates the expression of DNMT1 (Kishikawa et al., 
2002). Tolfenamic acid promotes Sp1 protein degradation and lowers APP, tau, and 
BACE1 expression as well as Aβ levels and improves cognition in mice (Abdelrahim 
et al., 2006; Adwan et al., 2011; Adwan et al., unpublished observation; Subaiea et al., 
in press). Tolfenamic acid is scheduled to be tested in AD patients in the near future.  
3. Discussion and conclusions  
Epigenetic changes that occur early in life can impact our health decades later. 
Various studies suggest that pathologic changes in AD can be reversed prior to the 
development of symptoms through epigenetic modifications (Fig. 1). Developmental 
exposure to lead (Pb) upregulates genes involved in AD late in life through 
mechanisms that involve DNA methylation and histone acetylation (Bihaqi et al., 
2011; Bihaqi & Zawia, 2012; Wu et al., 2008a). Persistent bidirectional changes in 
DNA methylation in response to earlier Pb exposure are reported with 
hypermethylation resulting in a latent reduction in gene expression (Alashwal et al., 
2012; Dosunmu et al., 2012). Moreover, cognitive impairment accompanies 
overexpression of Sp1, BACE1, APP and Aβ late in life following early exposure to 
Pb and consequential epigenetic alterations (Bihaqi et al., in press). Such 
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environmentally-induced changes on AD-related intermediates could be reversed via 
epigenetic mechanisms. Alternatively, active epigenetic changes are involved in 
memory formation and could be targeted for AD therapy. Modulation of epigenetic 
intermediates could be a means for upregulation of genes that promote learning and 
memory, or reversing epigenetic changes that are responsible for the overexpression of 
genes involved in AD pathology. As neurons have a very limited ability to regenerate, 
reversing pathological changes through targeting epigenetic intermediates seems to be 
a promising therapeutic approach.  
Interestingly, epigenetic targets in AD are also implicated in the pathophysiology of 
schizophrenia and depression (Covington et al., 2009; Gavin & Sharma, 2010). 
Depression is a common comorbidity in demented patients (Alzheimer's Association, 
2012; Holtzer et al., 2005). Psychotic symptoms, especially at later stages of the 
disease, are also frequent in AD (Alzheimer's Association, 2012; Ropacki & Jeste, 
2005). Besides AD, HDAC inhibitors have been explored for other disorders including 
schizophrenia and depression. For example, the HDAC inhibitor sodium butyrate 
shows antidepressant activity in mice (Schroeder et al., 2007). Sodium butyrate also 
protects against phencyclidine induced psychotic-like behavior in mice (Koseki et al., 
2012). It would be interesting to study the effects of HDAC inhibitors as epigenetic 
modifiers on cognitive as well as depressed and psychotic symptoms in AD patients. 
Epigenetic alterations reported in AD are summarized in Table 1. A major challenge 
for AD management is early diagnosis. Currently, no standard criteria are available for 
early or accurate detection of AD through reference values of biomarkers from 
patients CSF and blood samples or imaging results. Epigenetic changes in AD could 
 24 
 
offer a diagnostic tool for the disease especially that some changes occur long before 
the molecular pathology of AD develops. If such changes are identified and detected 
early, reversing them via epigenetic therapeutic approaches would prevent the 
triggering of alterations in gene expression and transcriptional cascade associated with 
the neuropathology of AD. Also establishing criteria for epigenetic changes in AD can 
help administer disease-modifying drugs, once they become available, early in the 
disease process. The use of epigenetics will likely be even more crucial as the field 
moves towards early and pre-symptomatic case detection and earlier attempts at 
intervention (Sperling et al., 2011). 
The side effects of epigenetic targeting should also be studied. Attention should be 
made for the consequences of epigenetic modifications that are involved in multiple 
pathways and which might serve various functions within different cells and organs. 
Identification of more specific targets and agents could be a way for minimizing 
toxicity. It is important to realize that drugs with epigenetic effects are already present 
on the market. Some drugs used for years like the antihypertensive agent hydralazine 
and the antiepileptic drug valproate are found to interfere with epigenetic pathways 
which explains their previously unknown mechanisms of action or some of their 
adverse effects and suggests that their use could be repurposed for other disorders 
where epigenetic alterations are desired (Csoka & Szyf, 2009).  
Our knowledge about epigenetics is still limited, some mechanisms have been studied 
more thoroughly like histone acetylation and DNA methylation, yet much remains to 
be revealed, especially when it comes to AD, memory and cognitive functions. 
Epigenetics is more upstream in AD pathology than the more common or conventional 
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targets such as BACE, γ-secretase, Aβ and tau and thus could be beneficial especially 
in early stages of the disease to prevent further transcription and accumulation of 
pathological intermediates. Screening for such modifications and diagnosis of AD at 
an early stage remain a challenge. Nevertheless, promoting epigenetic mechanisms 
that trigger memory formation and inhibit pathological events could be a novel and 
effective therapeutic approach for preventing or at least delaying the development of 
dementia. Epigenetics offer potential for AD where epigenetic changes are integrated 
in the disease pathology. While no disease-modifying candidate is available, more 
research is needed for the refinement of epigenetic targets and identification of 
specific agents that can improve cognition and prevent or slow AD. Although 
knowledge is still being gathered about this field of study, there is evidence that 
epigenetics could provide multi-target therapeutic approaches for AD. 
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Fig. 1. Epigenetic targets and therapeutic approaches for AD. DNA methylation 
and histone modification mediators involved in AD and potential therapeutic 
interventions under development reported in literature. Barrels = histones; (M) = 
methyl group; (Ac) = acetyl group. Abbreviations in the figure are as follows: DNMT, 
DNA methyltransferase; HAT, histone acetyltransferase; HDAC, histone deacetylase; 
SIRT, sirtuin. 
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Table 1 Some epigenetic changes in AD reported in literature. 
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Epigenetic Mark Change Reference 
HDAC2 Increase Graff et al., 2012 
HDAC6 Increase Ding et al., 2008 
SIRT1 Decrease Julien et al., 2009 
DNMT1 Decrease Mastroeni et al., 2010 
microRNA-101 Decrease Hebert et al., 2008 
microRNA-107 Decrease early in AD Wang et al., 2008b 
BACE1-AS Upregulated Faghihi et al., 2008 
Methylation on APP gene Hypomethylation West et al., 1995 
Methylation on APP, PS1, 
tau 
No change Barrachina & Ferrer, 
2009 
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Abstract  
Tau and its aggregates are linked to the pathology of Alzheimer’s disease (AD) and 
other tauopathies. Currently, they are being targeted to find the much needed 
treatments for such disorders. Tau belongs to a family of microtubule-associated 
proteins (MAPs) that promote microtubule assembly. When hyperphosphorylated, tau 
loses its normal function of binding to microtubules and becomes prone to form 
aggregates. Increased levels of hyperphosphorylated tau in the brain correlate with 
dementia. Specificity protein 1 (Sp1) is a transcription factor that is elevated in AD 
and is responsible for the transcription of AD-related genes including the amyloid 
precursor protein (APP), tau, and its cyclin dependent kinase-5 (CDK5) activators. 
Tolfenamic acid promotes the degradation of Sp1; previous studies from our lab 
demonstrated its ability to downregulate transcriptional targets of Sp1 like APP and 
thereby reduce amyloid beta (Aβ) levels, the main component of AD plaques. In this 
study, we administered two different doses of tolfenamic acid daily to APP knockin 
mice for one month, and used real time PCR and Western blot analyses to examine the 
changes in tau and CDK5 gene and protein expression within the cerebral cortex. Our 
results demonstrate that tolfenamic acid lowers tau mRNA and protein, as well as the 
levels of its phosphorylated form. Moreover, tolfenamic acid decreases the levels of 
the kinase involved in tau phosphorylation, CDK5. Thus, this repurposed drug inhibits 
the transcription of multiple intermediates in AD pathology through a common 
mechanism and may offer a therapeutic solution subsequent to its impending human 
biomarker study. 
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Introduction 
The microtubule associated protein tau (MAPT) was first isolated and recognized for 
its role in microtubule assembly in 1975 (Weingarten et al., 1975). In Alzheimer’s 
disease (AD) and other tauopathies, tau assembles forming pathological deposits. AD 
is the most common tauopathy where hyperphosphorylated tau aggregates as paired 
helical filaments (PHFs) and tangles (Grundke-Iqbal et al., 1986; Lee et al., 1991; 
Goedert, 1997; Lee et al., 2001; Brunden et al., 2009). The normal function of tau is to 
stabilize microtubules, and the exact cause of its aggregation is unknown. It has been 
found that tau hyperphosphorylation reduces its binding to microtubules and is 
suspected to play a role in its aggregation (Drechsel et al., 1992; Iqbal et al., 1994; 
Alonso et al., 1997; Goedert, 1997; Brunden et al., 2009). Hyperphosphorylated tau 
lacks its normal function of binding to microtubules and forms neurofibrillary 
aggregates (Beyreuther and Masters, 1996). Moreover, hyperphosphorylated tau 
suppresses microtubules assembly and can sequester normal tau and high molecular 
weight microtubule binding proteins, restraining their normal functions (Drechsel et 
al., 1992; Alonso et al., 1997; Iqbal et al., 2009; Iqbal et al., 2010; Medina, 2011). 
This suggests that phosphorylation regulates the functions of tau. The main enzymes 
responsible for tau phosphorylation are glycogen synthase kinase-3 beta (GSK3β) and 
cyclin-dependent kinase 5 (CDK5) among others.  
Specificity protein1 (sp1) is a transcription factor that is involved in AD pathology. 
Sp1 gene expression and protein levels are elevated within the frontal cortex of AD 
patients and animal models with AD-like pathology (Basha et al., 2005; Zawia and 
Basha, 2005; Santpere et al., 2006; Brock et al., 2008; Citron et al., 2008). Sp1 binds 
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to GC rich promoter regions within the amyloid precursor protein (APP) and tau genes 
and promotes their transcription (Salbaum et al., 1988; Pollwein et al., 1992; Hoffman 
and Chernak, 1995; Heicklen-Klein and Ginzburg, 2000; Docagne et al., 2004; Gao et 
al., 2005; Citron et al., 2008). Sp1 regulates the expression of tau and mutations on the 
Sp1 binding regions on the tau promoter decrease tau expression (Heicklen-Klein and 
Ginzburg, 2000; Gao et al., 2005). Sp1 protein (SP1) is co-localized with 
hyperphosphorylated tau in AD tangles (Santpere et al., 2006). Sp1 also regulates the 
transcription of CDK5 activators p39 and p35 with Sp1 binding motifs found on the 
promoter regions of CDK5, p39 and p35 (Ohshima et al., 1995; Ohshima et al., 1996; 
Ross et al., 2002; Valin et al., 2009). CDK5 is responsible for the phosphorylation of 
tau on sites that are unusually hyperphosphorylated in AD (Paudel et al., 1993; 
Ohshima et al., 1995). Tolfenamic acid, a drug available on the European market for 
migraine headaches, promotes SP1 degradation and lowers the expression of genes 
regulated by Sp1 including APP (Abdelrahim et al., 2006; Adwan et al., 2011). It is 
currently scheduled for a human biomarker study involving AD patients. This research 
study is designed to test the ability of tolfenamic acid to downregulate the expression 
of tau and CDK5 as players in the tangle pathology of AD by its unique capability to 
promote the degradation of SP1 (Fig. 1). This would provide more evidence for 
tolfenamic acid use in clinical neurodegenerative studies. 
Materials and Methods 
Animals. 
 Female hemizygous APP YAC transgenic mice line R1.40 (14-20 months old) were 
used in this study (The Jackson Laboratory). Animals were housed in designated 
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rooms within the animal facility at the University of Rhode Island. Mice were 
assigned into 3 groups of similar age variations, n= 6 in each group. Animals were 
administered 0, 5 or 50 mg/kg tolfenamic acid (Sigma-Aldrich) in corn oil everyday 
by oral gavage for 34 days. On day 35, mice were sacrificed and brain tissues were 
collected and stored at -80
ᵒ
C until further use. All experiments were performed in 
accordance with the standard guidelines and the protocol approved by the Institutional 
Animal Care and Use Committee of the University of Rhode Island.  
RNA isolation, cDNA synthesis and real time PCR. 
RNA was isolated from cerebral cortex tissue following the TRIzol
®
 Reagent method 
(Invitrogen), checked for integrity by NanoDrop (Thermo Scientific), and reverse 
transcribed to cDNA using iScript
TM
 Select cDNA Synthesis Kit following 
manufacturer’s instructions (Bio-Rad). About 1000 ng of RNA were diluted to 19.5 
µL with nuclease free water, then 3 µL Oligo (dT) mix, 6 µL 5x iScript Select reaction 
mix, and 1.5 µL of iScript reverse transcriptase were added. Samples were incubated 
at 42°C for 90 minutes then at 85°C for 5 minutes to terminate the reaction. All 
incubations were conducted using MJ Research MiniCycler
TM
 (Bio-Rad). Primer pairs 
for mouse tau, CDK5 β-actin and GAPDH were obtained from Invitrogen as follows: 
tau sense: 5’- GTG GCC AGG TGG AAG TAA AA -3’ and antisense: 5’- TGG AAG 
ACA CAT TGC TGA GG -3’; CDK5 sense: 5’- GGC TAA AAA CCG GGA AAC 
TC -3’, and antisense: 5’- CCA TTG CAG CTG TCG AAA TA -3’; β-actin sense: 5’- 
TGT TAC CAA CTG GGA CGA CA -3’, and antisense: 5’- TCT CAG CTG TGG 
TGG TGA AG -3’; GAPDH sense: 5’- GCCTTCTCTCCATGGTGGTAAA AGC 
TGA ACG GGA AGC TCA CT -3’, and antisense: 5’- AGG TCC ACC ACT GAC 
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ACG TTG-3’. Each real time PCR reaction mix contained 2 µL of cDNA, 1 µL of 
each primer, 8.5 µL nuclease free water and 12.5 µL SYBR
®
 Green PCR Master Mix 
(Applied Biosystems). Real time PCR was conducted using the 7500 Real Time PCR 
System (Applied Biosystems) following the standard protocol: 50°C for 2 minutes 
followed by 95°C for 10 minutes, then 40 cycles of 95°C for 15 seconds and 60°C for 
1 minute. Results were analyzed using the 7500 system software with relative 
quantification method and β-actin or GAPDH as endogenous control.  
Protein extraction and Western blot analyses 
Cerebral cortex tissue was homogenized with RIPA lysis buffer (10 mM Tris-HCl 
([pH 7.4], 150 mM NaCl, 1% Triton X-100, 0.1 SDS, 1 mM EDTA (Fisher 
Scientific), and 0.1% protease inhibitor cocktail (Sigma-Aldrich)). The homogenates 
were centrifuged at 10,600 x g for 10 minutes at 4°C and supernatants were collected. 
Protein concentration was determined using the Micro BCA Protein Assay Kit 
(Pierce). Protein extracts were stored at -80°C until further use. For Western blot 
analyses, approximately 40 μg of protein samples were separated onto 4–15% precast 
polyacrylamide gels (Bio-Rad) at 150 V for 1-2 hours and then transferred to PVDF 
membranes (GE-Healthcare). Membranes were blocked and incubated with the 
appropriate dilution of the specific primary antibody for 1-2 hours. The tested 
antibodies were used as follows: 1:1000 dilution of T9450 for total tau levels (Sigma-
Aldrich); 1:1000 of CDK5 #2506 (Cell Signaling); 1:1000 of P-tau Thr
181 
#5383 (Cell 
Signaling); 1:1000 of P-tau Ser
235
 ab30664 (Abcam); 1:5000 dilution of β-actin A2013 
(Sigma-Aldrich); or 1:2000 of GAPDH T9450 (Sigma-Aldrich), then the membranes 
were washed with TBST and incubated with the appropriate infrared dye-labeled 
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secondary antibody (Li-Cor) for 1 hour at room temperature in the dark. Infrared 
signal of Western blot bands was detected and quantified using an Odyssey
®
 Infrared 
Imaging System (Li-Cor). Western blot protein levels were normalized against the 
levels of the house keeping proteins β-actin or GAPDH. 
Statistical analysis 
Data were represented as the mean ± the standard error of the mean (SEM). Statistical 
analysis was performed using GraphPad Instat software (GraphPad software) and 
statistical significance was determined by one-way analysis of variance (ANOVA) and 
Tukey-Kramer multiple comparisons post-test. Results with a p-value of <0.05 were 
considered statistically significant, and were marked with asterisks accordingly. 
Results 
Targeting the neurofibrillary tau pathology of AD by influencing the transcription 
factor Sp1 is a new therapeutic approach that can be extended to other tauopathies. 
Studies from our lab have already provided evidence that tolfenamic acid crosses the 
blood brain barrier and is able to lower SP1 and subsequently reduce APP 
transcription and Aβ levels in mice brain (Adwan et al., 2011; Subaiea et al., 2011). 
The safety profile of tolfenamic acid has already been established. This drug has been 
approved and used in Europe for the management of migraine headaches and 
rheumatoid arthritis for years. In our experiments, we did not observe any toxic effects 
on animals administered tolfenamic acid. In this study tolfenamic acid was given daily 
to mice for 34 days to study the effects of promoting SP1 degradation by the drug on 
tau gene expression and protein levels. The data reported below also show the effects 
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of reducing SP1 on various intermediates in the tau pathology including CDK5 and 
phosphorylated tau (P-tau) on Ser 235 and Thr 181. 
Tolfenamic acid lowers tau gene expression and total tau levels in vivo 
By inducing SP1 degradation we hypothesized that tolfenamic acid would also reduce 
the gene expression of Sp1 transcription targets like tau (Abdelrahim et al., 2006; 
Adwan et al., 2011). Following the administration of tolfenamic acid to mice daily for 
34 days, tau gene expression was lowered by 48% with both the 5 and 50 mg/kg doses 
as determined by real time PCR (Fig. 2). One-way ANOVA p=0.0018, Tukey-Kramer 
multiple comparisons post-test p<0.001 for the control (C) vs 5 mg/kg group 
comparison, p<0.05 for C vs 50 mg/kg group. Furthermore, tolfenamic acid decreased 
total tau protein levels by 46% with both doses as measured by Western blot analysis 
(Fig. 3). One-way ANOVA p=0.014, Tukey-Kramer post-test p<0.05 for C vs 5 
mg/kg and for C vs 50 mg/kg. 
Tolfenamic acid decreases the gene and protein expression of CDK5 in mice 
As Sp1 also regulates CDK5 activators (Valin et al., 2009), we next tested the effects 
of tolfenamic acid on CDK5. We found that daily administration of tolfenamic acid to 
mice for a month lowered the gene expression of CDK5 in the cerebral cortex by 
about 50% (Fig. 4). One-way ANOVA p=2.8 10
-7
, Tukey-Kramer post-test p<0.05 
for C vs 5 mg/kg and for C vs 50 mg/kg. There was a lowering trend in CDK5 levels 
(Fig. 5) that was not significant when analyzed with one-way ANOVA p=0.059. 
However when comparing the 50 mg/kg dose group to the control by Tukey-Kramer 
test, the 40% lowering in CDK5 from control was statistically significant (p<0.05). 
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Tolfenamic acid reduces the expression of phosphorylated tau 
As phosphorylation of tau affects its function and its ability to bind to microtubules 
(Alonso et al., 1997; Sengupta et al., 1998; Alonso et al., 2008), it was important to 
test how phosphorylated tau is affected by the treatment. Levels of phosphorylated 
forms were analyzed by Western blotting using specific antibodies. P-tau Ser
235 
and P-
tau Thr
181
 were lowered by both doses of tolfenamic acid (Fig. 6, 7). Tau 
phosphorylated on Ser 235 was lowered by about 15%, one-way ANOVA p=0.0165, 
Tukey-Kramer post-test p<0.05 for C vs 5 mg/kg and for C vs 50 mg/kg. P-tau Thr
181
 
was lowered by about 30%, one-way ANOVA p=0.0112, Tukey-Kramer post-test 
p<0.05 for C vs 5 mg/kg and for C vs 50 mg/kg. 
Discussion  
Tolfenamic acid, a drug already available in the European market for the management 
of migraine headaches, represents a novel class of drugs that could be repurposed for 
AD due to its unique ability to promote the degradation of SP1 (Abdelrahim et al., 
2006; Adwan et al., 2011), a transcription factor that has been linked to AD tau and 
Aβ pathology (Docagne et al., 2004; Santpere et al., 2006; Brock et al., 2008; Citron et 
al., 2008). Previous studies from our lab demonstrate that by lowering SP1, tolfenamic 
acid is able to decrease the transcription of APP as well as Aβ levels in mice following 
2 weeks of daily administration (Adwan et al., 2011). Our studies also show that 
tolfenamic acid is readily available in the brain after dosing (Adwan et al., 2011; 
Subaiea et al., 2011).  
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Behavioral and immunohistochemical studies that took place at our lab have revealed 
that tolfenamic acid lowers the plaque burden and improves cognition in the APP 
transgenic mouse model used in this study (G. M. Subaiea, and N. H. Zawia, 
unpublished observations). These transgenic mice were chosen as a model of the 
amyloid pathology of AD, as they express Aβ plaques that are not found in wild type 
mice. Since cognitive impairment is better correlated with tau and Sp1 regulates the 
expression of tau (Heicklen-Klein and Ginzburg, 2000; Iqbal et al., 2009; Medina, 
2011), we wanted to study the effects of tolfenamic acid on the tau pathology in the 
same animals where we observed its cognitive benefits. Data presented within this 
manuscript demonstrate that tolfenamic acid lowers tau and CDK5 levels by inhibiting 
their transcription. The exact mechanism of action by which tolfenamic acid enhances 
SP1 degradation still remains to be established.  
During the past twenty years, drug discovery has focused on targeting intermediates 
mentioned in the amyloid hypothesis of AD including APP and Aβ, and so far no 
successful disease-modifying candidate has been found for this devastating disorder. 
Much less attention was paid to tau which is abnormally hyperphosphorylated and 
forms aggregates in AD. More recent studies have found a better correlation between 
tau and memory impairment in AD (Medina, 2011). In a transgenic mouse model that 
expresses plaques and tangles, lowering both soluble tau and Aβ caused cognitive 
improvement, while lowering only soluble Aβ did not improve cognition (Oddo et al., 
2006). Tangles are later manifestations of tau pathology and soluble phosphorylated 
tau is the species responsible for neurodegenerative damage (Iqbal et al., 2009; 
Medina, 2011). 
 67 
 
Tau and its abnormal phosphorylation are becoming targets for AD therapeutics. Tau 
knockdown by siRNA in vitro does not alter cell viability or the availability of 
microtubules (Morris et al., 2011). Probably because other microtubule associated 
proteins (MAPs) like MAP1b carry out similar functions to tau (Morris et al., 2011). 
The ability of tolfenamic acid to lower total tau levels is of great importance (Fig. 3). 
It was found that lowering soluble hyperphosphorylated tau rather than the insoluble 
tangles correlates with cognitive improvement (Iqbal et al., 2009; O'Leary et al., 2010; 
Medina, 2011). In fact, in a neurodegenerative mouse model, tau inhibition recovered 
memory function even though the buildup of tangles continued suggesting that tangles 
by themselves are not responsible for cognitive dysfunction (Santacruz et al., 2005). 
It is important to note that tolfenamic acid has been used for years, and that its 
interference with Sp1 should not be alarming since it was found that Sp1 is vital 
during early embryonic development only but not necessary for the following later 
stages of cell growth and differentiation (Marin et al., 1997). CDK5 is also important 
during nervous system development but not crucial later in life and thus is considered 
a promising target for AD where aberrant hyperphosphorylation and aggregation of 
tau is a major pathological finding (Lau et al., 2002; Piedrahita et al., 2010; Lopez-
Tobon et al., 2011).  
Administration of tolfenamic acid reduced the levels of tau phosphorylated at two 
sites, Ser 235 and Thr 181 (Fig. 6, 7). Both sites are phosphorylated by CDK5 and 
other kinases (Baumann et al., 1993; Liu et al., 2002). Tau phosphorylation occurs on 
multiple sites and is regulated by different kinases (Liu et al., 2006). Ser 235 was 
found to be one of 3 sites whose phosphorylation inhibits tau binding to microtubules 
 68 
 
(Sengupta et al., 1998). Moreover, it is one of the sites that are especially 
phosphorylated in PHF tau (Morishima-Kawashima et al., 1995; Hoffmann et al., 
1997).  
Interestingly we do not see much difference between the two doses used, suggesting 
that in order to get a dose response relationship we need to go lower beyond the 5 and 
50 mg/kg doses used. Such low doses would resemble those approved for migraine 
headaches management in Europe. 
Decreasing the levels of the tangle forming tau protein by reducing its transcription is 
a novel approach for targeting AD and other tauopathies. Data from this study 
demonstrate that this can be achieved by promoting the degradation of the 
transcription factor Sp1. Tolfenamic acid is able to lower tau, CDK5, phosphorylated 
tau at Ser 235 and Thr 181. Hence tolfenamic acid represents a promising candidate 
that targets both the amyloid and tau neurofibrillary pathways of AD through a unique 
transcription driven mechanism.  
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Figure II-1. The proposed transcriptional based mechanism of tau and CDK5 
downregulation by tolfenamic acid. Tolfenamic acid induces the degradation of the 
transcription factor Sp1, which reduces the transcription of tau and the activator for 
CDK5, resulting in a decrease in the total levels of tau as well as the pathogenic 
phosphorylated tau species and ultimately reducing the associated dementia.  
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Figure II-2. Tau relative gene expression in cerebral cortex tissues from mice 
treated with tolfenamic acid daily for 34 days. Mice were administered 0, 5 or 50 
mg/kg tolfenamic acid everyday for 34 days. Tau mRNA levels were measured in the 
cerebral cortex by real time PCR with β-actin as endogenous control as illustrated in 
the methods section. Values shown are the mean ± SEM, n=6 in each group, p=0.018 
as determined by one-way ANOVA with Tukey-Kramer post-test *p< 0.05; **p<0.01. 
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Figure II-3. Tau levels with tolfenamic acid administration. Total tau levels were 
analyzed in the cerebral cortex following daily administration of tolfenamic acid to 
mice for 34 days by Western blot analysis. Value shown are the mean ± SEM, n=5. 
Tau levels were normalized to the levels of the house keeping protein β-actin. One-
way ANOVA p=0.014, with Tukey-Kramer post-test *p<0.05. Insert shows 
representative control (C), 5 or 50 mg/kg treatment Western blot bands. 
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Figure II-4. CDK5 gene expression after tolfenamic acid treatment. CDK5 mRNA 
levels in mice cortex were measured with real time PCR with GAPDH as endogenous 
control as illustrated in the methods section. Values shown are the mean ± SEM, n=5. 
One-way ANOVA p<0.0001, ***p<0.001 as determined by Tukey-Kramer post-test.  
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Figure II-5. CDK5 following tolfenamic acid treatment. CDK5 levels in cerebral 
cortices of mice administered tolfenamic acid or control for 34 days were obtained by 
Western blot analysis. CDK5 levels were normalized to GAPDH levels. Values shown 
are the mean ± SEM, n=4. One-way ANOVA p=0.059. *p<0.05 according to Tukey-
Kramer post-test. Insert shows representative control (C), 5 or 50 mg/kg treatment 
Western blot bands. 
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Figure II-6. Levels of tau phosphorylated on Ser 235 after tolfenamic acid 
treatment. P-tau levels were measure by Western blot analysis and normalized to 
GAPDH as illustrated in the methods section. Values shown are the mean ± SEM, 
n=5. One-way ANOVA p=0.0165. *p<0.05 according to Tukey-Kramer post-test. 
Insert shows representative C, 5 or 50 mg/kg treatment Western blot bands.  
 
 86 
 
 
 87 
 
Figure II-7. Levels of tau phosphorylated on Thr 181 following tolfenamic acid 
exposure. P-tau levels were measured by Western blot and normalized to GAPDH 
levels. Value shown are the mean ± SEM, n=5. One-way ANOVA p=0.0112. *p<0.05 
according to Tukey-Kramer post-test. Insert shows representative C, 5 or 50 mg/kg 
treatment Western blot bands. 
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Abstract 
Since the introduction of the amyloid hypothesis of Alzheimer’s disease (AD) two 
decades ago, the plaque forming protein amyloid beta (Aβ) has been extensively 
targeted for AD therapy. However, so far no Aβ-lowering or any other mechanism-
based disease-modifying drug for AD is available. The effects of the drugs approved 
for AD are only symptomatic and cannot slow or stop the disease progression. Studies 
from our lab demonstrated that tolfenamic acid was able to lower the levels of the 
amyloid β precursor protein (APP) and its aggregative cleavage product Aβ by 
inducing the degradation of the transcription factor specificity protein 1 (Sp1). 
Similarly, tolfenamic acid also decreased the levels of tau, the main component of the 
neurofibrillary tangles in AD, and related deposits in other tauopathies. In this study, 
we examined whether tolfenamic acid alters the expression of the beta site APP 
cleaving enzyme 1 (BACE1) which is responsible for Aβ production and like APP and 
tau is under the transcriptional regulation of Sp1. Mice were administered two 
different doses of tolfenamic acid for one month, at the end of the study, BACE1 gene 
and protein levels as well as its activity were analyzed in the cerebral cortex. We 
found that tolfenamic acid was able to downregulate the expression of BACE1 and 
reduce its activity. Therefore, tolfenamic acid, a drug that has been used for years as 
anti-migraine, represents a novel class of AD therapeutics that targets the amyloid and 
tangle pathology of AD through multiple pathways due to its unique Sp1 lowering 
ability. 
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1. Introduction 
A century has passed since the disease was first described by Alois Alzheimer and 
about 35 million patients around the world suffer today from Alzheimer’s disease 
(AD) without any potential cure (Anstey et al., 2013; Selkoe, 2012). Furthermore, as 
no means for prevention of AD is available, the number of cases and the enormous 
economic cost of this devastating disease will continue to grow at an alarming rate. 
Knowledge on the pathophysiology of the disease continues to be gathered and reveal 
more possible drug targets and disease biomarkers. Two types of deposits are found in 
the AD brain, the amyloid plaques and the tau neurofibrillary tangles (Terry et al., 
1964; Tomlinson, 1982). A lot of attention has been directed to the plaques and their 
main constituent amyloid beta (Aβ) as well as intermediates in Aβ production or 
degradation, especially after the development of the amyloid cascade hypothesis 
which views Aβ as a major trigger in the pathology of AD (Hardy and Selkoe, 2002; 
Hardy and Higgins, 1992). 
Aβ is generated by the sequential enzymatic processing of the amyloid β precursor 
protein (APP) by β-secretase and γ-secretase (Shoji et al., 1992). The produced Aβ is 
normally secreted, but also can accumulate and form insoluble aggregates (Shoji et al., 
1992; Urbanc et al., 1999). The levels and activity of β-secretase are elevated in AD 
brains compared to control (Holsinger et al., 2002; Li et al., 2004). β-APP cleaving 
enzyme 1 (BACE1) is the main form of β-secretase that cleaves APP to generate Aβ 
(Cai et al., 2001). In an alternative pathway for processing APP, it can be cleaved by 
the enzyme α-secretase within the Aβ fragment resulting in non-amyloidogenic 
products (Selkoe, 1994). Aβ is found as 36-43 amino-acid-long peptides of which 
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Aβ40 is the most abundant and Aβ42 is the most aggregative and is proposed to trigger 
plaque formation in AD (Iwatsubo et al., 1994; Nakano et al., 1999; Naslund et al., 
2000).  
Up to now, five drugs that belong to two classes have been approved for AD, the 
cholinesterase inhibitors and the NMDA receptor antagonist memantine. These 
interventions aim at improving memory functions to some extent but do not stop the 
dementia and the ultimate loss of daily functioning caused by AD. Many other 
candidates were in preclinical and clinical trials but failed to demonstrate safety or 
efficacy. Several AD targets under investigation are within the amyloid pathway of 
AD including APP, β-secretase, γ-secretase and Aβ itself. Yet, no successful candidate 
that can change the course of AD has been found. 
Specificity protein 1 (Sp1) is a transcription factor that has been associated with the 
pathology of AD (Basha et al., 2005; Santpere et al., 2006; Zawia and Basha, 2005). 
Sp1 acts as a co-activator of APP transcription and regulates the expression of BACE1 
(Christensen et al., 2004; Docagne et al., 2004). Sp1 regulates gene transcription by 
binding to GC rich promoter regions in genes like APP and BACE1 whose binding to 
Sp1 increases their transcription (Christensen et al., 2004; Docagne et al., 2004; 
Hoffman and Chernak, 1995; Pollwein et al., 1992). Overexpression of Sp1 increases 
BACE1 promoter activity, while the decline in Sp1 reduces BACE1 gene transcription 
(Christensen et al., 2004). Immunohistochemical studies from our laboratory 
demonstrated that (Sp1 protein) SP1, APP, and Aβ co-localize in brain neurons, and 
that cortical and hippocampal areas with higher SP1 levels express more Aβ (Brock et 
al., 2008). Moreover, depletion of SP1 by siRNA silencing of the Sp1 gene reduces the 
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responsiveness of the human APP promoter by approximately 70% (Basha et al., 
2005). Therefore, changes in Sp1 expression can influence APP and BACE1 
transcription and consequently alter the levels of their downstream product Aβ. Sp1 
represents a potential AD target, where its abnormal and elevated expression has been 
associated with the disease decline (Brock et al., 2008; Christensen et al., 2004; Citron 
et al., 2008; Hoffman and Chernak, 1995; Santpere et al., 2006; Zawia and Basha, 
2005).  
Tolfenamic acid is a non-steroidal anti-inflammatory drug approved for migraine 
headaches in Europe. Tolfenamic acid induces the degradation of SP1 (Abdelrahim et 
al., 2006). Previous studies from our lab demonstrated that tolfenamic acid reduces the 
levels of SP1, APP, and Aβ (Adwan et al., 2011). Since the transcription factor Sp1 is 
vital for the regulation of several genes involved in AD including APP and BACE1, 
this research study was conducted to assess the effect of tolfenamic acid 
administration to APP yeast artificial chromosome (YAC) transgenic mice on BACE1, 
as a major enzyme in the production of Aβ, that is under Sp1 regulation. The 
hypothesis behind the use of tolfenamic acid for targeting Aβ in AD is illustrated in 
Fig. 1. 
2. Materials and Methods 
2.1. Animals 
Female hemizygous APP YAC transgenic mice line R1.40 were used in this study. 
The B6.129-Tg(APPSw)40Btla/Mmjax strain was obtained from the Jackson 
Laboratory, Bar Harbor, ME. Animals were bred in-house and the age of mice used in 
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this study was between 14-20 months. This AD animal model contains the entire 
human APP gene including the regulatory fragments and expresses elevated levels of 
Aβ especially the longer more aggregative forms Aβ42 and Aβ43 (Lamb et al., 1999; 
Lamb et al., 1997; Lehman et al., 2003). Animals were housed in designated rooms 
within the animal facility at the University of Rhode Island under standard conditions 
with food and water freely available. All efforts were made to minimize animal 
suffering, to reduce the number of animals used, and to utilize alternatives to in vivo 
techniques, if available. Mice were assigned into 3 groups of similar age variations, n= 
6 in each group. Animals were administered 0, 5 or 50 mg/kg tolfenamic acid (Sigma-
Aldrich, St. Louis, MO) in corn oil every day by oral gavage for 34 days. On day 35, 
mice were sacrificed and brain tissues were collected and stored at -80
ᵒ
C until further 
use. Studies of animal weights before and after tolfenamic acid administration came 
from previous animal exposures, Hartley guinea pigs were administered control or 50 
mg/kg tolfenamic acid 3 times a week for 4 weeks (n=3), and wild type C57BL/6 mice 
were treated with 0, 1, 5, 10, 25 or 50 mg/kg/day tolfenamic acid for 15 days, the full 
exposure scenario and other effects on APP and Aβ have already been published 
(Adwan et al., 2011). All experiments were performed in accordance with the standard 
guidelines and the protocol approved by the Institutional Animal Care and Use 
Committee of the University of Rhode Island. 
2.2. RNA isolation, cDNA synthesis and real time PCR 
RNA was isolated from cerebral cortex tissue following the TRIzol
®
 Reagent method 
(Invitrogen, Carlsbad, CA), checked for integrity by NanoDrop (Thermo Scientific, 
Wilmington, DE), and reverse transcribed to cDNA using iScript
TM
 Select cDNA 
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Synthesis Kit following manufacturer’s instructions (Bio-Rad, Hercules, CA). About 
1000 ng of RNA were diluted to 19.5 µL with nuclease free water, then 3 µL Oligo 
(dT) mix, 6 µL 5x iScript Select reaction mix, and 1.5 µL of iScript reverse 
transcriptase were added. Samples were incubated at 42°C for 90 minutes then at 85°C 
for 5 minutes to terminate the reaction. All incubations were conducted using MJ 
Research MiniCycler
TM
 (Bio-Rad, Hercules, CA). Primer pairs for mouse BACE1 or 
β-actin were obtained from Invitrogen (Carlsbad, CA) as follows: BACE1 sense: 5’-
ATGTGCACGATGAGTTCAGG-3’ and antisense: 5’- GCA GAG TGG CAA CAT 
GAA GA -3’; β-actin sense: 5’- TGT TAC CAA CTG GGA CGA CA -3’, and 
antisense: 5’- TCT CAG CTG TGG TGG TGA AG -3’. Each real time PCR reaction 
mix contained 2 µL of cDNA, 1 µL of each primer, 8.5 µL nuclease free water and 
12.5 µL SYBR
®
 Green PCR Master Mix (Applied Biosystems, Foster City, CA). Real 
time PCR was conducted using the 7500 Real Time PCR System (Applied 
Biosystems, Foster City, CA) following the standard protocol: 50°C for 2 minutes 
followed by 95°C for 10 minutes, then 40 cycles of 95°C for 15 seconds and 60°C for 
1 minute. Results were analyzed using the 7500 system software with relative 
quantification method and β-actin as endogenous control. 
2.3. Protein extraction and Western blot analyses 
Cerebral cortex tissue was homogenized with RIPA lysis buffer (10 mM Tris-HCl 
([pH 7.4], 150 mM NaCl, 1% Triton X-100, 0.1 SDS, 1 mM EDTA (Fisher Scientific, 
Rockford, IL), and 0.1% protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO)). 
The homogenates were centrifuged at 10,600 x g for 10 minutes at 4°C and 
supernatants were collected. Protein concentration was determined using the Micro 
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BCA Protein Assay Kit (Thermo Scientific Pierce, Rockford, IL). Protein extracts 
were stored at -80°C until further use. For Western blot analyses, approximately 40 μg 
of protein samples were separated onto 4–15% precast polyacrylamide gels (Bio-Rad, 
Hercules, CA) at 150 V for 1-2 hours and then transferred to PVDF membranes (GE-
Healthcare, Piscataway, NJ). Membranes were blocked and incubated with the 
appropriate dilution of the specific primary antibody for 1-2 hours, either 1:500 
dilution of MAB5308 for BACE1 levels (Millipore, Billerica, MA) or 1:5000 dilution 
of β-actin A2013 (Sigma-Aldrich, St. Louis, MO) were used. Then the membranes 
were washed with TBST four times and incubated with the appropriate infrared dye-
labeled secondary antibody (Li-Cor, Lincoln, NE) for 1 hour at room temperature in 
the dark. Infrared signal of Western blot bands was detected and quantified using an 
Odyssey
®
 Infrared Imaging System (Li-Cor, Lincoln, NE). Western blot bands were 
normalized against the levels of the house keeping protein β-actin. 
2.4. BACE1 activity assay 
BACE1 activity within the cerebral cortices of control and treated mice was measured 
using SensiZyme BACE1 activity assay kit CS1060 (Sigma-Aldrich, St. Louis, MO) 
following the manufacturer’s instructions. Briefly 100 µL of blank, standards, or 
samples containing 450 µg protein were loaded into wells pre-coated with anti-
BACE1 antibody. Samples were incubated for 2 hours at 4
ᵒ
C, after that, wells were 
washed 4 times then 50 µL of BACE1 substrate A was added to each well and 
incubated overnight at room temperature in a humidified chamber. On the next day 50 
µL of the colorimetric substrate B reagent mixture was added to the wells and 
incubated at room temperature for 3 hours. At the end of the incubation period, 
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absorbance was measured at 405 nm using Spectra Max UV/Vis Spectrometer (GMI, 
Ramsey, MN) and BACE1 activity was calculated in ng/mL using the standard curve. 
2.5. Statistical analysis 
Data was represented as the mean ± the standard error of the mean (SEM). Statistical 
analysis was performed using GraphPad Instat software (GraphPad software, San 
Diego, CA) and statistical significance was determined by one-way analysis of 
variance (ANOVA) and Tukey-Kramer multiple comparisons post-test or using a two-
tailed Student's t-test. Results marked with asterisks were significantly different
 
from 
the control group (p<0.05). 
3. Results 
3.1. Tolfenamic acid is safe and well-tolerated by exposed animals 
Tolfenamic acid has been used for years in humans for migraine headaches and 
rheumatoid arthritis. In our experiments, we did not observe any toxic effects of 
tolfenamic acid on animals. Tolfenamic acid was well tolerated and no changes in 
weight occurred in wild type mice administered 0, 1, 5, 10, 25 or 50 mg/kg/day doses 
for 15 days and Hartley guinea pigs administered 50 mg/kg 3 times a week for 4 
weeks (Fig. 2A and B). Data obtained by our collaborators at M. D. Anderson Cancer 
Center also found that chronic administration of tolfenamic acid was not toxic and had 
no adverse effects on animals’ weight, hematocrit, stomach or intestinal lining 
integrity compared to control (M. R. Basha, unpublished observations). 
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3.2. Tolfenamic acid lowers BACE1 gene and protein expression in vivo 
Following the administration of tolfenamic acid to APP YAC transgenic mice daily 
for 34 days, BACE1 gene expression within the cerebral cortex was lowered by 30% 
with both the 5 and 50 mg/kg doses as determined by real time PCR (Fig. 3). One-way 
ANOVA p=0.0116, Tukey-Kramer multiple comparisons post-test p<0.05 for the 
control vs 5 mg/kg group and for control vs 50 mg/kg group. Similar results were 
found in wild type animals administered 0 or 5 mg/kg/day tolfenamic acid for 15 days. 
On Day 4 there was a lowering trend that did not reach statistical significance, 
Student’s test p=0.122 (Fig. 4A), while after 15 days of daily dosing BACE1 gene 
expression was lowered by 33%, Student’s test p=0.0312 (Fig. 4B). Furthermore, 
tolfenamic acid daily administration for about a month decreased BACE1 protein 
expression levels by 6% and 16% in the transgenic APP YAC mice with the 5 and 50 
mg/kg doses respectively as measured by Western blot analysis (Fig. 5). Student’s t-
test p<0.05. 
3.3. Tolfenamic acid reduces BACE1 activity 
We then checked how the activity of the enzyme BACE1 in the cerebral cortex was 
affected following the exposure of APP YAC transgenic mice to tolfenamic acid for 
34 days. BACE1 enzyme activity was reduced by 45% with the 5 and 50 mg/kg/day 
doses as determined by BACE1 activity assay (Fig. 6). One-way ANOVA p=0.0197, 
Tukey-Kramer multiple comparisons post-test p<0.05 for the control vs 5 mg/kg and 
for C vs 50 mg/kg group. 
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4. Discussion 
Research studies including those conducted in our lab demonstrate that the 
transcription factor Sp1 is involved in AD pathology (Brock et al., 2008; Christensen 
et al., 2004; Citron et al., 2008; Docagne et al., 2004; Santpere et al., 2006). Sp1 
regulates the expression of APP, BACE1 and tau (Christensen et al., 2004; Docagne et 
al., 2004; Heicklen-Klein and Ginzburg, 2000; Hoffman and Chernak, 1995). SP1 co-
localizes with APP and Aβ in brain neurons as well as with tau in tangles (Brock et al., 
2008; Santpere et al., 2006). Due to its unique role in the transcription of AD related 
genes, targeting Sp1 is a novel and promising approach for discovering disease-
modifying drugs for AD. In cancer, the reduction of SP1 by tolfenamic acid is 
beneficial due to the subsequent drop in the transcription of certain genes that are 
involved in tumor growth and formation such as the vascular endothelial growth factor 
and survivin (Abdelrahim et al., 2006; Basha et al., 2011; Eslin et al., 2011; Konduri et 
al., 2009).  
So far, no drug has been found to slow or stop the progression of AD, all available 
medications alleviate symptoms of the disease to a certain limit, but do not affect any 
of its pathological features or prevent its progression. Aβ and other factors involved in 
its processing are being targeted for AD. Vaccines against Aβ are under development 
although several have failed in clinical trials due to life threatening adverse effects 
such as meningoencephalitis (Delrieu et al., 2012; Schnabel, 2011). The structural 
properties of the BACE active site limit the ability for development of inhibitors for 
this enzyme (Tamagno et al., 2012). Whereas γ-secretase inhibitors have failed due to 
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toxicity associated with the inhibition of Notch signaling (Mattson, 2004; Ross and 
Imbimbo, 2010). 
Our previous work demonstrated that tolfenamic acid was able to downregulate 
proteins implicated in AD pathology including APP and Aβ (Adwan et al., 2011). In 
this study, we confirmed that tolfenamic acid also lowers BACE1, another protein that 
is regulated by Sp1 and takes part in the amyloidogenic pathway of AD (Christensen 
et al., 2004). Following tolfenamic acid daily administration for about 1 month, the 
expression and activity of BACE1 were reduced in APP YAC transgenic mice. In 
these animals, tolfenamic acid also lowered SP1, APP and Aβ as well as improved 
cognition as determined by behavioral tests using the Morris water maze and the Y-
maze (G. M. Subaiea and N. H. Zawia, unpublished observations). By lowering SP1, 
tolfenamic acid was able to decrease tau gene and protein expression in the same 
animals as well (L. I. Adwan and N. H. Zawia, unpublished observations). 
The safety of tolfenamic acid has already been established and the drug has been used 
for migraine headaches in Europe for years (Hakkarainen et al., 1982; Hakkarainen et 
al., 1979; Myllyla et al., 1998; Tokola et al., 1984). In our studies, no signs of toxicity 
were observed throughout the exposure periods, the weights of wild type mice and 
Hartley guinea pigs administered tolfenamic acid in our preliminary studies were 
presented in Fig. 2, with no irregular changes in weights throughout the duration of 
dosing. This exposure resulted in the reduction of the levels of brain APP and Aβ 
(Adwan et al., 2011). 
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Tolfenamic acid is a multi-target drug candidate for AD that affects both the amyloid 
and neurofibrillary tau pathology of AD. By decreasing Sp1, tolfenamic acid was able 
to lower BACE1 expression and activity. The safety of tolfenamic acid use in humans 
has already been established as it has been approved and used for years in Europe for 
migraine headaches. Hence it represents a promising agent that can be repurposed for 
AD and was recently scheduled to be tested in AD patients. 
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Figure III-1. Downregulation of BACE1 and APP by tolfenamic acid. Tolfenamic 
acid stimulates the degradation of the transcription factor Sp1, which reduces the 
transcription of APP and BACE1, consequently reducing the expression of BACE1 
and APP as well as the aggregative product Aβ and the associated AD pathology. 
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Figure III-2. Weights of animals following treatment with tolfenamic acid. (A) 
Averaged weights of wild type mice before and after daily treatment with 0, 1, 5, 10, 
25, or 50 mg/kg/day tolfenamic acid for 15 days, n=5. (B) Weekly measurements of 
the weights of Hartley guinea pigs administered 0 or 50 mg/kg tolfenamic acid 3 times 
a week for 4 weeks, n=3. Values shown are the mean ± SEM. 
 
 112 
 
 113 
 
Figure III-3. BACE1 relative gene expression within the cerebral cortices of 
R1.40 transgenic mice following tolfenamic acid exposure. Hemizygous transgenic 
APP YAC mice were administered 0, 5 or 50 mg/kg/day tolfenamic acid for 34 days. 
BACE1 mRNA levels were measured in the cerebral cortex by real time PCR with β-
actin as endogenous control as illustrated in the methods section. Values shown are the 
mean ± SEM, n=5 in each group, p=0.0116 as determined by one-way ANOVA with 
Tukey-Kramer post-test *p<0.05. 
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Figure III-4. BACE1 relative gene expression in cerebral cortex tissues from mice 
treated with tolfenamic acid daily. Wild type C57BL/6 mice were given 0 or 5 
mg/kg/day tolfenamic acid for 15 days. BACE1 mRNA levels were measured on (A) 
day 4 and (B) day 16 after dosing within the cerebral cortex by real time PCR with β-
actin as endogenous control. For full details on the exposure scenario refer to Adwan 
et al., (2011). Values shown are the mean ± SEM, n=4, *p<0.05 as determined by 
Student’s t-test.  
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Figure III-5. BACE1 levels in R1.40 APP transgenic mice cortex after tolfenamic 
acid administration. BACE1 levels were analyzed in the cerebral cortex following 
daily administration of 0, 5, or 50 mg/kg tolfenamic acid to mice for 34 days by 
Western blot analysis. Value shown are the mean ± SEM, n=4. BACE1 levels were 
normalized to the levels of the house keeping protein β-actin. *p<0.05 according to 
Student’s t-test. 
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Figure III-6. BACE1 enzyme activity in the cerebral cortex of APP YAC 
transgenic mice following tolfenamic acid exposure. BACE1 activity was measured 
using SensiZyme BACE1 activity assay kit from Sigma-Aldrich as illustrated in the 
methods section. Values shown are the mean ± SEM, n=5. One-way ANOVA 
p=0.0197. *p<0.05 as determined by Tukey-Kramer post-test.  
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Abstract 
Tolfenamic acid reduces the levels of the transcription factor specificity protein 1 
(Sp1) and as a result decreases the transcription of genes regulated by Sp1 like the 
amyloid precursor protein (APP), beta-site APP cleaving enzyme 1 (BACE1) and tau. 
These genes are implicated in the pathology of Alzheimer’s disease (AD). They are 
major mediators in the formation of the characteristic plaques and tangles. Exposure to 
the environmental toxicant lead (Pb) is associated with AD pathology. Early life Pb 
exposure results in the upregulation of AD-related genes later in life. The gene and 
protein expression of APP and its aggregative product amyloid beta (Aβ) were 
increased following earlier Pb exposure. These results were replicated in 
neuroblastoma cells, rodents and primates. The effects of Pb were mediated by the 
upregulation of Sp1. This study was designed to examine the effects of tolfenamic 
acid on basal and Pb-induced levels of intermediates within the amyloid cascade 
hypothesis. Differentiated SH-SY5Y neuroblastoma cells were exposed to control, 
tolfenamic acid, or sequentially to Pb followed by control or tolfenamic acid. Our 
results show that while Pb upregulated SP1, APP and Aβ, tolfenamic acid was able to 
lower their expression. These results along with previous data from in vivo 
experiments provide evidence that tolfenamic acid represents a drug candidate, which 
can reduce the pathology of AD and may mitigate the damage of environmental risk 
factors associated with this disease which is mainly sporadic in nature. 
 
Keywords 
Alzheimer’s disease, Amyloid β, Lead, SH-SY5Y cells, Sp1, Tolfenamic acid. 
 
 
 
 
 
Abbreviations 
Aβ, amyloid β; AD, Alzheimer’s disease; ANOVA, analysis of variance; APP, 
amyloid precursor protein; BACE, β-site APP cleaving enzyme; FBS, fetal bovine 
serum; SEM, standard error of the mean; Sp1, specificity protein 1; SP1, Sp1 protein. 
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Introduction 
Tolfenamic acid induces the degradation of the transcription factor specificity protein 
1 (Sp1) (Abdelrahim et al., 2006). In mice, lowering Sp1 protein (SP1) resulted in the 
reduction of the amyloid precursor protein (APP) and its cleavage product amyloid β 
(Aβ), which are involved in Alzheimer’s disease (AD) pathology (Adwan et al., 2011). 
This reduction is attributed to the transcriptional regulation of APP by Sp1 (Hoffman 
and Chernak, 1995; Docagne et al., 2004). Sp1 also regulates the transcription of the 
beta site APP cleaving enzyme 1 (BACE1) that processes APP and generates Aβ 
(Christensen et al., 2004). Overexpression of SP1 increases BACE1 promoter activity, 
while the decline in SP1 reduces BACE1 gene transcription (Christensen et al., 2004).  
AD is characterized by the deposition of β-amyloid plaques and neurofibrillary tau 
tangles within the brain. Senile plaques are aggregates of Aβ peptides that are about 40 
amino acids long (Glenner and Wong, 1984; Masters et al., 1985). Aβ is normally 
secreted, but also can accumulate resulting in the formation of insoluble aggregates 
which depends on the rates of Aβ synthesis and elimination (Shoji et al., 1992). The 
majority of AD cases are sporadic and the exact causes of the disease are unknown. 
According to the amyloid cascade hypothesis of AD, Aβ and its plaque aggregates 
formed by the amyloidogenic breakdown of APP trigger events that cause the 
neurodegeneration and dementia in AD, and therefore have been targeted for potential 
therapeutics (Hardy and Higgins, 1992; Hardy and Selkoe, 2002). However, so far no 
disease-modifying drug for AD is available.  
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Sp1 is a co-activator of APP transcription and siRNA silencing of the Sp1 gene 
reduces the responsiveness of the human APP promoter by 70% (Docagne et al., 2004; 
Basha et al., 2005). Immunohistochemical studies from our lab demonstrated that SP1, 
APP, and Aβ co-localize in rodent and primate brain neurons, and that cortical and 
hippocampal areas with higher SP1 levels express more Aβ (Brock et al., 2008). 
Therefore, any process that affects Sp1 could also influence APP transcription and 
alter the expression of its downstream pathogenic product Aβ. This makes Sp1 a 
plausible target for AD therapeutics. 
Exposure to the environmental toxicant lead (Pb) is considered a risk factor with 
detrimental effects on various organs especially the brain (Zawia and Basha, 2005; 
White et al., 2007; Zawia et al., 2009). Experiments conducted at our lab demonstrated 
that Pb exposure early in life results in AD like pathology in vitro and in vivo, in 
rodents and primates. Pb administration caused the upregulation of Sp1, APP, Aβ as 
well as other intermediates implicated in AD later in life (Basha et al., 2005; Wu et al., 
2008; Zawia et al., 2009; Bihaqi et al., 2011; Huang et al., 2011; Bihaqi and Zawia, 
2012). Our most recent studies revealed that these molecular changes were 
accompanied by cognitive deterioration in mice administered Pb compared to controls 
(Bihaqi et al., in press). 
In this study, we utilized an in vitro model of Pb exposure established in our lab to test 
the ability of tolfenamic acid to rescue proteins upregulated following early Pb 
exposure, which induces molecular consequences that resemble pathological events 
observed in late onset AD (Huang et al., 2011; Bihaqi and Zawia, 2012). Following 
cell viability studies, differentiated SH-SY5Y cells were exposed to Pb, tolfenamic 
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acid or both agents in chronological order and the changes on SP1, APP and Aβ were 
examined in comparison to control. 
Materials and methods 
Cell culture. Human neuroblastoma SH-SY5Y cells were purchased from American 
Type Culture Collection (ATCC, Manassas, VA). Cells were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM)/F12 (Life technologies, Grand 
Island, NY) with 10% fetal bovine serum (FBS) and 100 U/mL penicillin, 100 μg/mL 
streptomycin and 2 mM L-glutamine at 5% CO2 and 37°C. Cells were subcultured at 
10
5
 cells/mL in flasks containing 10 mL each and were allowed to attach over night 
then differentiated in 10 μM all-trans retinoic acid (Sigma-Aldrich, St. Louis, MO) in 
DMEM/F12 containing 1% FBS and 100 U/mL penicillin, 100 μg/mL streptomycin 
and 2 mM L-glutamine for 1 week following previously published methods (Jamsa et 
al., 2004; Huang et al., 2011). Neurite outgrowth was examined at 48, 72 h and 6 days 
(Jamsa et al., 2004) and the medium was changed every 48 h. Following 
differentiation, cells were exposed to control, tolfenamic acid, Pb or both. 
Exposure to Pb and tolfenamic acid. For treatments, stock solutions of 10 mM Pb 
acetate in sterile distilled water and 100 mM tolfenamic acid in DMSO were prepared. 
The stock solutions were diluted in DMEM/F12 media containing 1% FBS, 100 U/mL 
penicillin, 100 μg/mL streptomycin and 2 mM L-glutamine for the different 
exposures. The concentration of DMSO in the cell culture media was maintained at 
0.05% for control and all other treatments. Differentiated SH-SY5Y cells were 
exposed to 0 or 25 μM tolfenamic acid for 96 h with the media changed every 48 h. 
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Cells were also exposed to 50 μM Pb for 48 h after which the media was removed and 
replaced with media containing 0, 25 or 50 μM tolfenamic acid for another 48 h. Cells 
exposed to media containing 0.05% DMSO, 1% FBS, 100 U/mL penicillin, 100 
μg/mL streptomycin and 2 mM L-glutamine with no Pb or tolfenamic acid were used 
as controls. 
Cell viability assay. SH-SY5Y cells were loaded at 10
4
 cells per 100 µL in each well 
onto 96-well plates and were allowed to attach overnight then were differentiated 
using 100 μM all-trans retinoic acid. Differentiated cells were exposed to 0, 1, 2.5, 5, 
10, 50, or 100 μM tolfenamic acid for 12, 24, or 72 h with six replicates per group. 
Cells were incubated at 37˚C with 5% CO2 and 90% humidity. Cell viability was 
determined using the Vybrant
®
 MTT cell proliferation assay kit following the 
manufacturer’s instructions (Life technologies, Grand Island, NY). Absorbance at 570 
nm was measured using Spectra Max UV/Vis Spectrometer (GMI, Ramsey, MN) and 
cell viability was determined in treatment groups as a percentage from control. 
RNA isolation, cDNA synthesis and real time PCR. RNA was isolated from cells 
following the TRIzol
®
 Reagent method (Invitrogen, Carlsbad, CA), checked for 
integrity by NanoDrop (Thermo Scientific, Wilmington, DE), and reverse transcribed 
to cDNA using iScript
TM
 Select cDNA Synthesis Kit following the manufacturer’s 
instructions (Bio-Rad, Hercules, CA). About 1000 ng of RNA were diluted to 19.5 µL 
with nuclease free water, then 3 µL Oligo (dT) mix, 6 µL 5x iScript Select reaction 
mix, and 1.5 µL of iScript reverse transcriptase were added. Samples were incubated 
at 42°C for 90 minutes followed by 85°C for 5 minutes to terminate the reaction. All 
incubations were conducted using MJ Research MiniCycler
TM
 (Bio-Rad, Hercules, 
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CA). Primer pairs for human APP or GAPDH were obtained from Invitrogen 
(Carlsbad, CA) as follows: APP sense: 5′- GCC AAA GAG ACA TGC AGT GA -3' 
and antisense: 5′- CCA GAC ATC CGA GTC ATC CT -3′; GAPDH sense: 5′- AGC 
TGA ACG GGA AGC TCA CT -3′, and antisense: AGG TCC ACC ACT GAC ACG 
TTG -3′. Each real time PCR reaction mix contained 2 µL of cDNA, 1 µL of each 
primer, 8.5 µL nuclease free water and 12.5 µL SYBR
®
 Green PCR Master Mix 
(Applied Biosystems, Foster City, CA). Real time PCR was conducted using the 7500 
Real Time PCR System (Applied Biosystems, Foster City, CA) following the standard 
protocol: 50°C for 2 minutes followed by 95°C for 10 minutes, then 40 cycles of 95°C 
for 15 seconds and 60°C for 1 minute. Results were analyzed using the 7500 system 
software with relative quantification method and GAPDH as endogenous control.  
Protein extraction and Western blot analysis. Cytoplasmic and nuclear extractions 
were carried out using NE-PER nuclear and cytoplasmic extraction reagents according 
to the manufacturer’s instructions (Thermo Scientific Pierce, Rockford, IL). Protein 
concentration was determined with the Micro BCA protein assay kit (Pierce, 
Rockford, IL). For SP1 Western blotting, samples containing 20 μg nuclear protein 
were separated onto 4–15% precast polyacrylamide gels (Bio-Rad Hercules, CA) at 
150 V for 1-2 h and then transferred to PVDF membranes (GE-Healthcare, 
Piscataway, NJ). Membranes were blocked and incubated with the appropriate 
primary antibody for 1-2 h, either 1:500 dilution of ABE135 for SP1 levels (Millipore, 
Billerica, MA) or 1:2000 of GAPDH T9450 (Sigma-Aldrich, St. Louis, MO), then the 
membranes were washed with TBST and incubated with the appropriate infrared dye-
labeled secondary antibody (Li-Cor, Lincoln, NE) for 1 h at room temperature in the 
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dark. Infrared signal of Western blot bands was detected and quantified using 
Odyssey
®
 Infrared Imaging System (Li-Cor, Lincoln, NE). Western blot results were 
normalized against the levels of the house keeping protein GAPDH. 
ELISA Aβ40 assay. Levels of Aβ40 in cell culture media were measured using human 
Aβ40 kit JP27713 (IBL, Gunma, Japan). The kit is solid-phase sandwich
 
ELISA with 
highly specific antibody that is 100% reactive with human Aβ40 with a sensitivity of 
5.00 pg/mL. The kit measures Aβ40 cleaved N terminal side by any cause. The assay 
was conducted following manufacturer’s instructions with minor modifications. One 
hundred µg protein as determined by Micro BCA protein assay kit (Thermo Scientific 
Pierce, Rockford, IL) in 100
 
µL EIA buffer and assay standards were added in 
triplicates to 96-well plates pre-coated with anti-human Aβ mouse IgG MoAb. The 
plates were incubated overnight at 4°C, and washed 7 times using the 40X diluted 
wash buffer supplied with the kit (0.05% Tween 20 in phosphate buffer), and 100 μL 
labeled antibody was added and incubated for 1 h at 4°C, the wells were washed again 
9 times, and then 100 μL of tetramethylbenzidine was added as a coloring agent, and 
incubated in the dark for 30 minutes at room temperature. Finally 100 μL of 1N 
H2SO4 was added to stop the reaction, and absorbance was measured at 450 nm using 
Spectra Max UV/Vis Spectrometer (GMI, Ramsey, MN). The concentration of Aβ in 
unknown samples was calculated as pg/mg total protein using the standard curve 
obtained. 
Statistical analysis. Data was represented as the mean ± the standard error of the mean 
(SEM). Statistical analysis was performed using GraphPad Instat software (GraphPad 
software, San Diego, CA) and statistical significance was determined by one-way 
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analysis of variance (ANOVA) and Tukey-Kramer multiple comparisons post-test. 
Results with p-values <0.05 were considered significantly different
 
from the group in 
comparison and were marked accordingly. 
Results 
Tolfenamic acid cell viability studies in differentiated neuroblastoma cells 
The viability of SH-SY5Y cells differentiated using all-trans retinoic acid was 
examined following treatments with 0-100 µM tolfenamic acid. The results show that 
tolfenamic acid did not cause any cytotoxicity until the highest dose of 100 µM after 
24 h and 72 h of exposure (p<0.001) (Fig. 1). This suggests that the effects of 
tolfenamic acid on cell viability are time and dose-dependent. Overall one-way 
ANOVA reported a p-value less than 0.0001; one-way ANOVA p=0.8164 for groups 
in the 12 h exposure; p<0.0001 for the 24 h treatment groups; and p<0.0001 for groups 
in the 72 h exposure. Based on these results, we chose the doses of 25 and 50 µM of 
tolfenamic acid for the following exposure experiments.  
Tolfenamic acid lowers SP1 
Exposure of differentiated SH-SY5Y cells to 50 μM Pb for 48 h followed by control 
for 48 h induced the expression of SP1 by 47% which did not reach statistical 
significance according to Tukey-Kramer post-test when compared to control exposed 
cells. However, when Pb treatment for 48 h was succeeded by exposure to 25 μM 
tolfenamic acid for 48 h, SP1 levels were decreased by 75% compared to control 
which was deemed statistically significant according to Tukey-Kramer post-test 
(p<0.05), and by 83% when compared to SP1 levels in cells exposed to Pb for 48 h 
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followed by control for 48 h (p<0.01). Overall one-way ANOVA between all groups 
reported a p-value equal to 0.003 (Fig. 2). 
Effects of tolfenamic exposure on APP gene expression 
Treatment of cells with tolfenamic acid for 96 h reduced the gene expression of APP 
compared to control by 18% that was not statistically significant. Whereas the 
exposure of cells to Pb for 48 h and control for 48 h increased APP gene expression by 
23% which did not reach statistical significance when compared to control. 
Tolfenamic acid treatment after Pb lowered the Pb-induced APP gene expression in 
differentiated neuroblastoma cells by 60% from control (p<0.05) and by 67% from 
cells exposed to Pb for 48 h followed by control for 48 h (p<0.01). Overall one-way 
ANOVA reported a p-value of 0.001 (Fig. 3). 
 
Tolfenamic acid lowers the levels of Aβ40 induced by Pb 
Aβ levels were increased by 42% in differentiated SH-SY5Y cells after treatment with 
Pb for 48 h followed by control for additional 48 h (Fig. 4). This increase was 
significant when compared to cells treated with control for 96 h with the media 
changed every 48 h according to Tukey-Kramer multiple comparison test (p<0.01). 
When treatment of SH-SY-5Y cells by Pb for 48 h was followed by treatment with 25 
µM tolfenamic acid for 48 h, there was a trend of reduction in Aβ levels in the media 
by 10% compared to treatment with Pb for 48 h and control for 48 h. Aβ levels were 
decreased by 56% with the 50 µM tolfenamic concentration for 48 h following prior 
Pb exposure for 48 h which was significant compared to Aβ levels in the media of 
cells exposed to Pb for 48 h and control for 48 h (p<0.001); and Aβ levels were 
reduced by 37% compared to cells exposed to control for 96 h (p<0.05). However, 
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treatment of cells with 25 µM tolfenamic acid for 96 h did not change Aβ levels within 
the media. The overall one-way ANOVA p-value between groups was p<0.0001. 
Discussion 
The transcription factor Sp1 has been linked to the pathology of AD (Zawia and 
Basha, 2005; Santpere et al., 2006; Citron et al., 2008). Sp1 promotes the transcription 
of APP, BACE1 and tau, which are considered to be key pathological intermediates in 
AD. Data from our lab demonstrated that the non-steroidal anti-inflammatory drug 
tolfenamic acid lowers SP1, APP, Aβ, BACE1, and tau in mice (Adwan and Zawia, 
Unpublished observations; Adwan et al., 2011). The toxic effects of Pb on health have 
been described in the literature, experiments from our lab showed that Pb induced the 
expression of AD related genes and proteins including Sp1, APP, Aβ, and tau (Basha 
et al., 2005; Wu et al., 2008; Huang et al., 2011; Bihaqi and Zawia, 2012). Hence, 
tolfenamic acid and Pb represent two agents that have opposing effects when it comes 
to AD related processes. 
Tolfenamic acid has been used for rheumatoid arthritis and migraine headaches in 
Europe for years and its safety for use in humans was established. In neuroblastoma 
cells, low doses of tolfenamic acid did not affect cell viability (Fig. 1). A decrease in 
cell viability with tolfenamic acid was observed at the higher concentration of 100 µM 
and at the longer periods of exposure of 24 h and 72 h. The outcomes of tolfenamic 
acid on cell viability were dose and time dependent. 
To study the effects of tolfenamic acid on AD related genes and proteins in 
neuroblastoma cells, we chose the 25 and 50 µM concentrations which did not affect 
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cell viability based on our results. The 50 μM dose chosen for Pb exposure came from 
our previous cell viability and exposure studies with the same cell line (Huang et al., 
2011; Bihaqi and Zawia, 2012). Our results show that the exposure of differentiated 
SH-SY5Y neuroblastoma cells to tolfenamic acid for 48 h after 48 h of Pb exposure 
decreased SP1 levels significantly compared to cells exposed to control for 96 h or Pb 
followed by control for 48 h each (Fig. 2). Furthermore, tolfenamic acid significantly 
reduced APP gene and Aβ expression that was induced by Pb exposure but not the 
basal levels of APP and Aβ (Figs. 3 and 4). 
The 25 μM dose of tolfenamic acid was able to decrease SP1 levels and APP gene 
expression induced by prior Pb exposure. However, Aβ levels were only decreased 
significantly by the 50 μM tolfenamic acid exposure after Pb. As tolfenamic acid 
affects transcription, time is an important factor for observing its effects and in this 
study, although the 25 μM tolfenamic acid was very effective in lowering SP1 and 
APP gene expression following Pb administration, this drastic change was not 
translated into Aβ lowering probably due to insufficient time. For example, our 
previous studies showed that even though APP gene transcription was lowered with 
tolfenamic acid daily administration in mice for three days, APP protein levels were 
not lowered at that time (Adwan et al., 2011). Whereas the levels of both the APP 
gene and protein were decreased after two weeks of tolfenamic acid daily 
administration to mice (Adwan et al., 2011). 
About 90% of AD cases are sporadic and are referred to as late onset AD with age 
being the major risk factor (Alzheimer's Association, 2012). Our lab has demonstrated 
that early Pb exposure replicates pathological events observed late in life in AD within 
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various in vitro and in vivo models (Basha et al., 2005; Wu et al., 2008; Bihaqi et al., 
2011; Huang et al., 2011; Bihaqi and Zawia, 2012). In this manuscript, we use prior 
Pb exposure as a model that produces an upregulation of AD related intermediates 
including APP and Aβ by inducing the transcription factor Sp1, in a matter that 
resembles the environmentally inflicted late onset AD. After Pb exposure, we exposed 
the cells to tolfenamic acid, in order to test its ability to reverse the events caused by 
Pb. Our results show that tolfenamic acid was able to rescue the cells from the 
pathological increase in SP1, APP and Aβ. Hence tolfenamic acid represents a 
promising agent for AD which has been selected for testing in AD patients and may be 
useful in environmentally-induced AD pathogenesis. 
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 Figure IV-1. Cell viability of differentiated SH-SY5Y cells following tolfenamic 
acid exposure. Neuroblastoma cells were differentiated and exposed to 0, 1, 2.5, 5, 
10, 25, 50 or 100 μM tolfenamic acid for 12 h, 24 h, or 72 h and cell viability was 
studied using MTT as illustrated in the methods section. Values shown are the mean ± 
SEM, n=6 in each group, overall one-way ANOVA p<0.0001, one-way ANOVA 
p=0.8164 for groups in the 12 h exposure; p<0.0001 for groups in the 24 h; and 
p<0.0001 for groups in the 72 h exposure. ***p<0.001 compared to the corresponding 
control group from the same time duration of exposure as determined by Tukey-
Kramer post-test. 
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Figure IV-2. SP1 levels in differentiated SH-SY5Y cells after treatment with 
control or Pb followed by control or by tolfenamic acid. SH-SY5Y cells were 
differentiated using 100 μM all-trans retinoic acid and exposed to control (C) for 96 h 
with the media changed every 48 h; 50 μM Pb for 48 h followed by control for another 
48 h; or 50 μM Pb for 48 h followed by 25 μM tolfenamic acid (TA) for 48 h. Values 
shown are the mean ± SEM. Three independent experiments were performed in 
triplicates. SP1 levels were normalized to the levels of the house keeping protein 
GAPDH. One-way ANOVA p=0.003, with Tukey-Kramer post-test *p<0.05 
compared to C, ††p<0.01 compared to 48 h Pb followed by 48 C exposure group. 
Insert shows representative SP1 and GAPDH Western blot bands from 96 h control 
(C); 48 h Pb treatment followed by 48 h control; or 48 h Pb exposure followed by 48 h 
tolfenamic acid (TA) treatment. 
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Figure IV-3. APP gene expression in differentiated SH-SY5Y cells exposed to 
tolfenamic acid, Pb or both. Differentiated neuroblastoma cells were exposed to 
control (C) or 25 μM tolfenamic acid (TA) for 96 h with the media changed every 48 
h, cells were also exposed to 50 μM Pb for 48 h followed by C, 25 or 50 μM 
tolfenamic acid for 48 h. APP gene expression was measured by real time PCR with 
GAPDH as endogenous control as illustrated in the methods section. One-way 
ANOVA p=0.001. Tukey-Kramer post-test *p<0.05 compared to C, ††p<0.01 
compared to 48 h Pb followed by 48 C exposure group. 
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Figure IV-4. Aβ levels in differentiated SH-SY5Y cells exposed to tolfenamic acid, 
Pb or both. Differentiated neuroblastoma cells were exposed to control (C) or 25 µM 
tolfenamic acid (TA) for 96 h with the media changed every 48 h; or 50 µM Pb for 48 
h followed by either C, 25, or 50 µM tolfenamic acid for 48 h. Aβ levels within the 
media were measured using ELISA as explained in the methods section. Overall one-
way ANOVA p<0.0001 between all groups. Tukey-Kramer post-test *p<0.05 
compared to 25 µM TA group; +p<0.05, ++p<0.01 compared to 96 h C group and 25 
µM TA group; †††p<0.001 compared to 48 h Pb followed by 48 C group and 
compared to 48 h Pb followed by 48 h 25 µM TA  group 
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